CN101381409A - N-terminally chemically modified protein compositions and methods - Google Patents

N-terminally chemically modified protein compositions and methods Download PDF

Info

Publication number
CN101381409A
CN101381409A CNA2008101276757A CN200810127675A CN101381409A CN 101381409 A CN101381409 A CN 101381409A CN A2008101276757 A CNA2008101276757 A CN A2008101276757A CN 200810127675 A CN200810127675 A CN 200810127675A CN 101381409 A CN101381409 A CN 101381409A
Authority
CN
China
Prior art keywords
csf
pegization
goods
rabbit
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008101276757A
Other languages
Chinese (zh)
Other versions
CN101381409B (en
Inventor
O·B·金斯勒
N·E·加布里尔
C·E·发拉
R·B·迪普林斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23250903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101381409(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN101381409A publication Critical patent/CN101381409A/en
Application granted granted Critical
Publication of CN101381409B publication Critical patent/CN101381409B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.

Description

Protein composition that N-is terminally chemically modified and method
The application is to be February 8 nineteen ninety-five the applying date, and application number is 95191454.5, and denomination of invention is divided an application for the application for a patent for invention of " protein composition that N-is terminally chemically modified and method ".
Invention field
The present invention generally speaking relates to the protein modification field, and, more particularly relate to protein and analogue thereof are adhered to neck city (term used herein " protein " and " polypeptide " or " peptide " these terms of water soluble polymerizer, as do not do other explanation and all refer to the same meaning). the invention still further relates to the novel method that is used for the terminal modified protein of N or its analogue and the composition of gained. on the other hand, the present invention relates to terminally chemically modified G-CSF composition of new N and relevant preparation method. the invention still further relates to the Interferon, rabbit that has of chemically modified.
Background of invention
At present; why treatment can obtain with suitable form and liberal quantity with protein. and the operability of recombinant protein causes the progress of protein formulations and chemically modified aspect. and one of purpose of this chemically modified is exactly a protein protection. and chemical attachment can stop contacting of proteolytic ferment and protein skeleton itself effectively, thereby has stoped proteinic degraded.Other advantage is included under the certain environmental conditions, increasing proteinic stability of treatment and cycling time and reduce its immunogenicity. the review article of describing protein modification and fused protein is: Francis Focus on Growth Factors, 3:4-10 (in May, 1992) is (by Mediscript, Morntview Court, Friern Barnet Land, London N20, OLD, UK publishes).
Polyoxyethylene glycol (" PEG ") is exactly a kind of this class chemically modified part, it is used for preparation treatment with proteinaceous product (verb " PEGization " (pegylate) mean adhere at least one PEG molecule). and for example Adagan is the PEG modified forms of adenosine deaminase, has been got permission to be used for the treatment of serious composite immune deficiency disorders; The sudismase of PEGization has entered the clinic trial stage of treatment head injury; The alpha-interferon of PEGization is tested in the I clinical trial phase of treatment hepatitis; Also entered the preclinical test stage according to another the report glucocerebrosidase of PEGization and the methemoglobinemia of PEGization. adhere to polyoxyethylene glycol to the proteoclastic provide protection (Sada that appears in the newspapers; Deng J.Fermentation Bioengineering 71:137-130; 1991); the method of adhering to specific polyalkylene glycol moiety is referring to U.S. Patent No. 4; 179; 337; Davis et al.; " non-immunogenicity polypeptide "; announce on December 18th, 1979. and U.S. Patent No. 4; 002,531, Royer; " polyoxyethylene glycol is to the product of the modification and the production thereof of enzyme "; if announced on January 11st, 1977. wanting has more fully understanding to this field, can be referring to " Enzymes as Drugs " such as Abuchowski (J.S.HolcerbergandJ.Roberts, eds.pp.367-383 page or leaf (1981)).
Other water soluble polymerizer that has used such as ethylene glycol, propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone gathers-1,3-dioxolane (poly-1,3-dioxolane), gather-1,3, the 6-trioxane, the EMA anhydride copolymer, polyamino acid (or single aggressiveness or random copolymer).
For peg molecule, can it be added on the protein by several different methods.Generally speaking, peg molecule is to be linked on the protein molecule at the reactive group of finding on the protein molecule by one. amino, as on the lysine residue or the N-end on amino be generally used for this class and adhere to.For example, Royer (U.S. Patent number 4,002,531, see above-mentioned) think and can utilize standard reductive alkylation reaction that peg molecule is attached on the enzyme .Wright in disclosed EP 0 539 167 on April 28th, 1993, think in " Peg Imidates and ProteinDerivates Thereof " that the peptide and the organic double compound that have free amino group can be modified by the direct derivative of PEG or relevant water-soluble organic polymer.Shaw relates to the number that is used for adhering to by the reactive amino group lysine residue of peg molecule in the modifying protein in February 27 nineteen ninety in the laid-open U.S. Patents numbers 4,904,584.
" G-CSF ", granulocyte colony-stimulating factor are a kind of concrete treatment through chemically modified and induce the fast breeding of neutrophilic granulocyte with protein .G-CSF and be discharged in the blood, thereby the treatment effect is provided in anti-infective.
The open EP 0 401 384 of European patent has described material and the method that is used to prepare the G-CSF that is attached with peg molecule on December 12 nineteen ninety disclosed being entitled as " granulocyte colony-stimulating factor of chemically modified ".
Report G-CSF and the analogue thereof modified among the EP 0 473 268 of on March 4th, 1992 disclosed being entitled as " continuity discharges and comprises a water-soluble polymeric medicinal compositions on the peptide molecule covalent attachment ", described the use of the derivative that water-soluble granular a polymer such as a polyoxyethylene glycol produced on various G-CSF and the covalent attachment thereof.
Has an active polypeptide of human myelomonocyte colony-stimulating factor in what on October 4th, 1989, disclosed EP 0 335 423 reported a kind of modification.
Another example is the IL-6 of PGEization, is being entitled as " hIL-6 of modification " (referring to common unsettled U.S.S.N.07/632,070). EP 0 442 724 in disclose peg molecule be attached on the IL-6 molecule.
Disclosed EP 0 154 316 reported that the aldehyde of a lymphokine (Lymphokine) and a polyoxyethylene glycol reacts on September 11st, 1985.
Yet relating to, many methods of adhering to polymer to protein molecule use certain part as spacer group. these parts often have antigenicity. can carry out a kind of tresylchloride method that does not relate to spacer group, but because the use of tresyl chloride can produce malicious byproduct, so be difficult to this method production for treating product.Referring to Francis etc.: the stability of pharmaceutical grade protein: the strategy of intravital degradation pathway and protein stabilization (Eds.Ahern., T.and Manning, M.C.) (plenum, New York, 1991).Simultaneously also can be referring to Delgado etc., the eds. such as .Fisher that " activate coupling PEG to the application of protein in the immune affinity cell preparation " by Tresyl chloride, the water system is separated in cytobiology and Application in Biotechnology, Plenum Press, N.Y.N.Y., 1989 pp.211-213.
Chamow etc. (Bioconjugat ē Chem.5:133-140 (1994)) have reported that CD4 immunosorption element (immanoadhesin) is by modifying with mono methoxy poly glycol aldehyde generation reductibility alkanisation. the author reports that 50% CD4-Ig carries out the MePEG modification under the controlled condition of PEGization level of response.Ibid, sees 137 pages.The author has also reported external, the CD4-Ig that modifies is negative correlation in conjunction with the ability of (to albumen gp120) and the degree of its MePEGization. and ibid, equally also can be referring to Rose et al., Bioconjugate Chemistry 2:154-159 (1991) has reported in the literary composition that linking group carbohydrazide (carbohydrazide) optionally is attached on the C-terminal carboxyl(group) of protein substrate (Regular Insulin).
Yet, in whole field or relate in the field of specified protein and also do not have a kind of method can allow water soluble polymerizer optionally be attached on the N-end of protein such as G-CSF. What is more, the method that exists provides non-selective attachment reaction on any reactive group at present, no matter these groups be in protein (for example, the lysine side-chain group), still on the N-end. this will cause the heterogeneity of product. for example, the G-CSF molecule of PEGization, contain the polyalkylene glycol moiety that number is different from other molecule in some molecule. in above-mentioned reaction, may form a kind of heterogeneity mixture such as a molecule that contains 5 lysine residues, some molecules contain 6 peg molecules, have 5 in some molecules, have 4 in some molecules, have 3 in some molecules, have 2 in some molecules, and have 1 even a peg molecule and also do not have. and in having the molecule of some polyoxyethylene glycol, peg molecule may not can in different molecules be attached to identical position.
More than these all be exploitation treatment with the PEGization proteinaceous product not in sharp factor. when developing this class medicine, product is bioactive predictablely to seem exceptionally important. for example, superoxide-dismutase non-selectively with peg molecule bonded situation under, the enzyme that a part is modified completely lose activity (P.McGoff et al.Chem.Pharm.Bull.36:3079-3091 (1988)) if. these therapeutic proteins each between-lot in composition is had any different, people can't predict its biological activity. different loci bonded peg molecule stability is different, and this situation may cause these molecules to dissociate out from protein.Certainly, if these molecules be adhere at random and therefore RANDOM SOLUTION from, treatment just can not accurately be predicted with proteinic pharmacokinetics so. consider that from human consumer's angle be not quite similar different cycling times in batches, so also may be inaccurate on the dosage.Consider that from the producer's angle treatment of getting permission to come into the market will increase trouble with proteinic preservation. in addition, the aforesaid method none provides the selective N-terminal chemically modified of no connection portion (between protein and the polymer).If share the connection portion, because possible antigenicity may have a negative impact.
Therefore, still needing can the terminally chemically modified protein of selective N and analogue, comprises that method the present invention of G-CSF and total Interferon, rabbit (following is that example is illustrated with the protein of these two kinds of chemically modifieds just) has set forth this needs from all many-sides.
The present invention's general introduction
The present invention relates to N-terminally chemically modified proteinic basically all-goods and used method. unexpectedly the G-CSF of the terminal chemically modified of N-demonstrates the undiscovered advantage aspect stable of all kinds of institutes of other G-CSF that contains a chemically modified on another site of this molecule. more beat all is present method at the G-CSF that is used for preparing the chemically modified of N-end, find to use the standard reductive alkylation reaction that the condition of optionally modifying the N-end can be provided, and this method can be widely used in other protein (or its analogue) and G-CSF. surprisingly, utilize the standard reductive alkylation reaction, its end product-with amine key and water-soluble polymer bonded protein, much more stable than identical polymer/protein connector with amido linkage (amide link age). the protein that another one is modified like this (following just described as embodiment) is to have Interferon, rabbit (consensus interferon).Therefore, will describe in detail as top, the present invention has the content of all many-sides of the special modification that relates to chemically modified protein matter (or its analogue) and specified protein.
On the one hand, the present invention relates to the goods and the method for homogeneous basically of the G-CSF (or its analogue) of the terminal chemically modified of N-. the G-CSF of mono-PEG that the terminal single PEGization of N-has been described among the embodiment below is more stable than the G-CSF of the single PEGization of other type. in addition, since the N-end of G-CSF molecule in reaction process easily and peg molecule approaching, the terminal PEGization ratio of N-is higher, so this method operates and relatively has advantage.
The invention still further relates to a kind of standard reductive alkylation reaction type. this reacts the amino group of activator matter optionally or its analogue N-terminal residue, thereby make water-soluble polymer part selectivity be attached to the N end. provide goods and (if using polyoxyethylene glycol) of the homogeneous basically of polymer/protein bound molecule to have the goods that polyalkylene glycol moiety directly is coupled to the PEGization protein molecule on the protein portion like this. this method that is used for G-CSF and total Interferon, rabbit is described below, and these contents provide others of the present invention.
The accompanying drawing summary
Figure 1A is-the color atlas replica at the G-CSF ion-exchange chromatography peak of PEGization.
The SDS-PAGE figure of the single PEGization G-CSF of Figure 1B all kinds.
Fig. 2: line A is the SEC-HPLC figure of recombinant human methylenedisulfonyl G-CSF standard; Line B is the SCM-PEG-GCSF reaction mixture; Line C is the G-CSF of the terminal PEGization of N-; Line D is the G-CSF of the single PEGization of 35 Methionins; Line E is the G-CSF. of Methionin 41 single PEGization
Fig. 3 A, 3B and 3C are the G-CSF of the terminal PEGization of N-for the figure of the HPLC after endoproteinase (endoproteinase) SV8 peptase is cut, 3A; 3B is the G-CSF of the single PEGization of 35 Methionins; 3C is the G-CSF. of Methionin 41 single PEGization
Fig. 4 is a bar graph, be shown in external, the G-CSF kind of single PEGization and the not bioactive comparison of standard of PEGization.
Fig. 5 A and 5B have shown the bioactive analytical results of G-CSF derivative of in vivo single PEGization, Fig. 5 A shows the G-CSF of hamster through the terminal PEGization of subcutaneous injection N-, the mean value of white count behind the G-CSF of the G-CSF of the single PEGization of 35 Methionins or Methionin 41 single PEGization, Fig. 5 B show the final average white blood cell count area under curve behind the G-CSF of the above-mentioned various single PEGization of the single subcutaneous injection derivative.
Fig. 6 A, 6B and 6C scheme for the SEC-HPLC of the stable gained of the G-CSF of the G-CSF of the terminal PEGization of research N-or the single PEGization of 35 Methionins. and Fig. 6 A is at pH6.0, the SEC-HPLC figure of the G-CSF stability of the terminal single PEGization of research N-under 4 ℃ of conditions, Fig. 6 B are the G-CSF figure of the single PEGization of 35 Methionins under the same terms. and Fig. 6 C is presented under pH6.0 and 4 ℃ further the G-CSF results of stability to the single PEGization of 35 Methionins. and the time (" T ") is represented the sky.
Fig. 7 has shown that screen analysis (size exclusion) the HPLC analytical results of reaction mixture in the process of standard reductive alkylation reaction takes place for rh-G-CSF and methoxy polyethylene glycol aldehyde (MW6kDa).
Fig. 8 has shown reaction mixture screen analysis (size exclusion) the HPLC analysis chart with MPEG (also at MW=6kDa) N-hydroxyl succinyl-ester.
Fig. 9 is single N-terminal M PEG-GCSF joiner (the MPEG aldehyde by the rh-G-CSF different molecular weight makes through the reductibility alkylation reaction, and wherein the molecular weight of MPEG is 6kDa, 12kDa and 20kDa) total white cell response situation in back of single subcutaneous injection dosage.
Describe in detail
The present invention relates to the goods of basically homogeneous of the terminal chemical modifying protein of N-and used Method.
On the one hand, the present invention relates to the composition of G-CSF of N-end chemical modification and used method thereof.
This method (be used for the end modified G-CSF of N-and standard reductive alkylation reaction method) provides the mixture of the basically homogeneous of single aggressiveness/protein attachment. and " basically homogeneous " used herein means each polymer of observing/protein attachment molecule and all only contains a polymer moieties. perhaps can comprise the unreacted protein of (namely lacking polymer moieties) in the goods. among the embodiment below, confirm by peptide mapping (peptide mapping) and N-end sequencing, at least contain single aggressiveness of 90%/protein attachment in the goods of preparing, the unreacted protein content is no more than at most 10%. preferably, the terminal single PEG compound matter content of N-should reach 95% (as below described in the embodiment) of goods at least, most preferably, the terminal single PEG compound matter of N-account for goods 99% or higher. this single aggressiveness/protein attachment has biologically active. the homogeneity that the G-CSF goods of the terminal PEGization of the N-of " basically homogeneous " provided herein mean these goods is enough to demonstrate the superiority that the homogeneous goods have, for example, be easy to the different pharmacokinetics in batches of prediction in clinical practice.
People can select to prepare polymkeric substance/protein connector molecule mixture, advantage provided herein is, people can select the single aggressiveness/ratio of protein connector in mixture. like this, if necessary, people just can prepare the range protein mixture of the polymer molecule that has different numbers and adhere to (such as 2,3,4 or the like), and combine with the single aggressiveness/protein connector that utilizes the inventive method to prepare, just can obtain the mixture of booking list aggressiveness/protein connector ratio.
The embodiment that uses G-CSF is provided below; As mentioned above; G-CSF is the treatment protein that is used for the treatment of hematopoietic disorders. in general; G-CSF useful in the invention process can separate from the mammal organism; The product of chemical synthesis process as selecting perhaps; Or the product that obtains by prokaryotes or the exogenous dna sequence dna of eucaryote host expresses; Wherein these DNA can obtain from genome or cDNA clone or by DNA is synthetic. suitable prokaryotes host comprise various bacteriums (asE. Coli); Suitable eukaryote host comprise yeast (as S. Cerevisiae) and mammalian cell (as: Chinese hamster ovary cell, MC). according to used host's difference, the G-CSF expression product may be by the carbohydrate institute glycosylation in Mammals or other eukaryotic cell, or also can comprise an initial methionine residues (at the-1) in the non-glycosylated .G-CSF expression product. though the G-CSF that preferably recombinates (particularly from E.coli), the present invention have predicted and have used arbitrarily or whole maximum commercial practicality of this class form of G-CSF in other biology.
Existing some G-CSF analogues of report have biological function, and these molecules also can be chemically modifieds, for example, and one or more peg molecules in the interpolation.The G-CSF analogue is in U.S. Patent No. 4,810, existing report in 643.The tool report has the example of bioactive other G-CSF analogue that AU-A-76380/91 is arranged, EP 0 459 630, EP 0 272703, described in EP 0 473 268 and the EP 0 335 423 those, though the activity of the disclosed every kind of analogue of report is not provided in the literary composition. also can be referring to AU-A-10948/92, PCTUS 94/00913 and EP 0 243 153.
In general, G-CSF and analogue thereof useful among the present invention can be by carrying out chemically modified program provided herein optionally to modify the terminal alpha-amino group of N-, the required biological property of test products obtained therefrom, biological activity test for example provided herein is determined. certainly, if desired non-human mammal is carried out this class treatment, can use the inhuman G-CSF of reorganization, as the G-CSF product of the mouse of recombinating, ox and dog etc. for example, referring to PCT WO 9105798 and PCT WO 8910932.
Therefore, another aspect of the present invention comprises the composition of the G-CSF analogue of the terminal chemically modified of N-. as mentioned above, the G-CSF analogue can comprise have aminoacid addition, disappearance and/or substitute (with the G-CSF aminoacid sequence described in the following embodiment 1 comparatively speaking) product.Time expection performance function is for being attached on the G-CSF acceptor and the analogue of non-essential N-end with the G-CSF analogue of the generation of selective stimulating neutrophil leucocyte by PEGization when the N-end for those, see Hill et al., PNAS-USA 90:5167-5171 (1993); Also can be referring to PCT US 94/00913.
The polymer molecule that uses can be selected from water-soluble polymer.(for reductive alkylation process on glycopeptides described herein, polymer should have single reaction aldehyde radical). selective polymerisation thing molecule should be water miscible, make it want the bonded protein molecule in water surrounding, deposited phenomenon can not take place, for example in the physiological environment. consider from standard reductive alkylation reaction angle, the polymer molecule of selecting should have a reaction aldehyde radical, so just can control extent of polymerization according to the inventive method. and polymer can be a branch or not branched.Therepic use for the end product goods, preferred polymerizable molecular should be medicinal acceptable. whether those skilled in the art should be able to make in treatment according to this polymkeric substance/protein connector is used for selecting required polymkeric substance, if in treatment, use, then should consider its dosage, cycling time is to proteoclastic resistibility and some other factor.For G-CSF, the available means of testing that provides is herein found out, those skilled in the art also should select suitable means of testing at other therapeutic protein. and water-soluble polymer is freely optional: top listed (background parts) various molecules and dextran or poly-(n-V-Pyrol RC), polyoxyethylene glycol, polypropylene glycol, polyoxytrimethylene/ethylene oxide (prolypropylene oxide/ethylene oxide) multipolymer, polyoxyethylene polyvalent alcohol and polyvinyl alcohol.
Consider that for optimization described below the molecular weight of polymkeric substance can be any size, and can be to have branch or not branched.For polyoxyethylene glycol, most preferred molecular weight is to be about 2kDa to (term " approximately " means in the polyoxyethylene glycol goods, and some molecules are greater than described molecular weight, and other molecules are less than described molecular weight) between about 100kDa.The following examples 1 and embodiment 2 relate to PEG6000, its selection is convenient to purifying and a suitable modular system is provided. and required treatment plan (the slowly-releasing time length that situation is for example required is depended in the use of other size, effectively talk about aspect biological activity if render a service, the accessibility of handling, antigenicity size or shortage and some other PEG are to the known effect of therapeutic protein and analogue thereof.
A concrete aspect of the present invention is exactly the G-CSF molecule of the terminal single PEGization of N-, it partly is made up of a polyalkylene glycol moiety and a G-CSF. for said composition, people can be from multiple peg molecule (with molecular weight and have or not branch etc.), peg molecule is to the ratio of G-CSF protein molecule in the reaction mixture, the type of the PEGization reaction of being carried out, the aspects such as type of the method for the G-CSF of acquisition selective N-terminal PEGization and the G-CSF that will use are selected.In addition, this composition and method also comprise the prescription of medicinal compositions, the treatment of medicament and production method.
Peg molecule is the same with their concentration in reaction mixture to the ratio of protein molecule, can change. in general, optimum proportion (is meant reaction efficiency, be not have unnecessary unreacted protein and polymer molecule in the reaction mixture) will measure according to selected molecular weight polyethylene glycol. in addition, the purifying of the terminal single PEGization product of the non-specific PEGization reaction that relates among the embodiment as present method and N-subsequently, ratio depend on the available reactive group number that can participate in reaction (be typically ∝ or
Figure A200810127675D0016171549QIETU
Amino). the protein that relates among the embodiment of this paper: the reaction ratio of PEG molecule is quite low to obtain to be essentially the product (each protein molecule is to 1.5 PEG molecules) of single PEGization.
In order to obtain the G-CSF of the terminal PEGization of N-, also there is multiple PEGization the reaction method aforesaid or standard reductive alkylation described in the embodiment 2 reaction below available. about the polymerization process of no linking group between polyalkylene glycol moiety and the protein portion exists at Franciset al: the stability of protein medicine: vivo degradation approach and make the strategy (Eds.Ahern. of protein stabilization, T.and Manning, M.C.Plenum, New York, 1991) had description in. in addition, Delgado et al., " by TresylChloride Activiation method coupling PEG to the application of protein in the immune affinity cell product " and Fisher et al., eds., the water system is separated in cytobiology and Application in Biotechnology, Plenum Press, N.Y.N.Y., relate among 1989 pp.211-213 and utilize tresyl chloride, there is not linking group to exist between polyalkylene glycol moiety and protein portion thereby make. this method is owing to producing malicious byproduct, so be difficult to the production for treating product.Relating to the N-hydroxyl succinyl-fat that uses carboxymethyl methoxy polyoxyethylene glycol in an example of the present invention. another embodiment as following lecture in more detail relates to use standard reductive alkylation reaction method.
Obtain the method (that is, if necessary, this part being separated from the part of other single PEGization) of the G-CSF goods of the terminal PEGization of N-can be in the G-CSF of the PEGization of associating molecule colony the product of purifying N-end PEGization.For example, in the following embodiments, the G-CSF of PEGization at first separates to obtain to have the single PEGization material (material that may have other a plurality of PEGization that contain identical apparent charge) of charge characteristic by ion-exchange chromatography, use sieve chromatography (size exclusion chromatography) to separate the product of single PEGization then. by this method, the G-CSF of the terminal single PEGization of N-to be separated from the material of the material of the single PEGization of other type and other a plurality of PEGization. other method is appeared in the newspapers. for example, PCT WO 90/04606, reported a kind of method of the PEG-of separation protein adduct mixture in (May 3 nineteen ninety is open), comprising separating (partitioning) protein adduct with the aqueous two phase system PEG/ that contains PEG.
On the other hand, the present invention also provides selectivity to obtain the method for the terminal chemically modified protein matter of N-(or its analogue). and following for a kind of standard reductive alkylation that utilizes reacts the method for carrying out protein modification, it utilizes obtainable monovalence amino (primary amino group) the dissimilar specific reaction of (Methionin is to N-terminal) to carry out the modification of specified protein.Under appropriate reaction conditions, successfully proteinic N-end has been carried out optionally modifying with the carbonyl that has a polymkeric substance. under the pH that can utilize epsilon-amino and protein N-terminal alpha-amino pKa difference on the lysine residue, carry out this reaction. by this selective modification, the control water-soluble polymers is attached on the protein: the connection of polymkeric substance mainly occurs in proteinic N-end, and other reactive group (as the side chain amino on the lysine residue) is not then significantly modified and taken place.
Even more important and surprisingly, the invention provides a kind of method of goods of the homogeneous basically for preparing single aggressiveness/protein connector molecule, need not use required being further purified of other chemically modified chemical process. in addition, product with amine key is more stable than the product that forms with amido linkage unexpectedly. during will studying in great detail below, this point obtains proof. more particularly, if use polyoxyethylene glycol, the present invention also provides does not have the antigenicity of possibility linking group, and has the polyalkylene glycol moiety that directly is coupled to protein portion and the protein of the terminal PEGization of N-of nontoxic byproduct.
But the reaction See Figure is described (sodium cyanoborohydride is the illustrative reductive agent among the figure):
Therefore, an aspect of of the present present invention content is the method for preparing polymkeric substance/protein connector, comprise: (a) under the standard reductive alkylation reaction conditions, to contain protein molecule and water-soluble polymers molecular reaction more than an amino, the pH of reaction solution should be suitable for selecting to activate the aminoterminal alpha-amino group of said protein molecule, so described water-soluble polymers is attached to described alpha-amino group group, and; (b) obtain reaction product. can from optional from unreacted molecule reaction product isolated, but for treatment with product, this is preferred.
Another aspect of the present invention content is this standard reductive alkylation reaction, it can optionally be attached to polymer molecule arbitrarily has on the alpha-amino protein at the N-end, and providing the goods of the homogeneous basically of a kind of single aggressiveness/protein connector. terminology used here " single aggressiveness/protein connector " means by a polymer moieties and is attached to the composition of forming on the protein portion (those connectors that also comprise use protein analogue as herein described). and single aggressiveness/protein connector has a polymer moieties that is positioned at (as the amino of lysine side-chain) on N-end rather than the side chain amino. and goods preferably contain the single aggressiveness/protein connector greater than 80%, the single aggressiveness/protein connector more preferably greater than 95%.
For the single aggressiveness/protein connector molecule colony of basic homogeneous, its reaction conditions should be to be attached on the N-end of desired protein with allowing the water-soluble polymers molecular selectivity.This reaction conditions generally causes the amino and terminal alpha-amino pKa difference of N-(pK is meant amino protonated and non-protonization respectively accounts for 50% o'clock pH) of Methionin. in general, for different protein, can use different pH so that the terminal alpha-amino group of N-obtains best the modification.
PH often also can influence the ratio of used polymer molecule and protein molecule. in general, if reaction solution pH is lower than pK, the polymer molecule ratio should substantially exceed protein molecule and be advisable that (that is: the alpha-amino group reactivity of N-end is few more, it is many more to reach the required polymkeric substance of top condition) if. pH is higher than pK, polymkeric substance then: the ratio of protein molecule unnecessary too big (reactive group that promptly obtains is many more, and required polymer molecule is few more).
Another essential condition that need consider is the molecular weight of polymkeric substance. and in general, the molecular weight of polymkeric substance is big more, and the polymer molecule number that is attached on the protein is few more. and same, when optimizing these parameters, whether polymer molecule has branch also should take in.In a word, polymericular weight high more (or branch is many more), polymkeric substance: proteinic ratio also should be high more.
Standard reductive alkylation reaction hereto, its reductive agent should be more stable at the aqueous solution, preferably only can reduce at formed western Buddhist alkali of reductibility alkylation reaction starting stage (Schiffbase). preferred reductive agent can be selected from sodium borohydride, sodium cyanoborohydride, boric acid dimethylamine, boric acid Trimethylamine 99 and boric acid pyridine. what use among the embodiment below is sodium cyanoborohydride.
The water-soluble polymers molecule can be above-described type, should possess single reaction aldehyde radical in its molecule is coupled on the protein molecule it. for polyoxyethylene glycol, use is used for being used for G-CSF coupling and PEG12000 and has Interferon, rabbit being coupled at and describing below. what deserves to be mentioned is for G-CSF, in present method, PEG 12000,20000 and 25000 were all successfully used. and the polyoxyethylene glycol propionic aldehyde (is seen U.S. Patent No. 5,252,714) stability has certain advantage owing to it has preferably in water.
As mentioned above, present method is widely used in having terminal alpha-amino any protein of N-and analogue thereof. for example, the proteinaceous product that obtains by the exogenous DNA of bacterial expression, because the result of bacterial expression, have an alpha-amino group on the methionine(Met) of its N-end (methionyl) residue. as mentioned above, comprise peptide, all be some peptide analogs and other modifying protein. protein analogue, the total Interferon, rabbit that aforesaid G-CSF analogue and non-natural exist all is applicable to this method.
Therefore, for the G-CSF of the terminal chemically modified of this N-, any G-CSF as herein described or its analogue all share (article that for example, ibid described those).Used among the following embodiment is the reorganization G-CSF that produces in the bacterium, have 174 amino-acid residues and an extra dl-methionine residue. as described herein, chemically modified can use any water-soluble polymers molecule described herein to carry out, and what use in the following examples is polyoxyethylene glycol.
Total Interferon, rabbit is an another kind of protein used in the present embodiment. it is following that what will describe is the single PEGization modification of carrying out protein N-end with the reaction of the reductibility alkanisation among the present invention, thereby prepare the total Interferon, rabbit of chemically modified. therefore, another aspect of the present invention relates to these goods. as used herein, joint owner's lymphocyte interferon is called " total Interferon, rabbit " at this, or " IFN-con ", meaning is a non-natural polypeptide, it mainly comprises those amino-acid residues that all natural human LeIF hypotype sequences are total, and it also is included in all hypotypes and does not have on common amino acid whose one or more positions, mainly betide the amino acid in this position, and under any circumstance, be not included in the arbitrary amino acid residue .IFN-con that does not come across this position at least one naturally occurring hypotype and comprise three aminoacid sequences, difference called after IFN-con1, IFN-con2 and IFN-con3, the United States Patent (USP) 4 that it is being owned together, 695,623 and 4,897, open in 471, this paper quotes it in full for your guidance. (United States Patent(USP) Nos. 4,897,471 and 4,695, use " α " name in 623, and this paper does not use). the dna sequence dna of coding IFN-con can synthesize the .IFN-con polypeptide by above-mentioned patent or other standard method and preferably pass through conversion or transfection synthetic dna sequence dna in host bacterium, especially E.coliExpress and produce. be that IFNcon is reorganization IFN-con.With method known to those skilled in the art with at Klein et al., J.Chromatog. 454: 205-215 (1988) but in the method purifying that is used for IFN-con1 described preferably exist E.coliIn the IFN-con of the IFN-con. purifying produced may comprise its mixture of isomers, as including first sulfonyl IFN-con1 among the IFN-con1 of purifying, that removes methionyl IFN-con1 and N-end closure removes methionyl IFN-con1 (Klein et al., Arc.Biochem.Biophys. 276: 531-537 (1990)).As selection, IFN-con can comprise the isomer of specific isolation, available isomeric form of coming IFN-con separated from one another such as the technology of isoelectric focusing well known by persons skilled in the art.
Therefore, another aspect of the present invention content is the total Interferon, rabbit of chemically modified, wherein said total Interferon, rabbit is to be selected from IFN-con1, IFN-con2, and during the IFN-con3. chemically modified with water-soluble polymers as herein described PEG for example, and the reductive alkylation process on glycopeptides that is used for the terminal selective chemical modification of N-. the embodiment 3 of this paper has described the chemically modified of IFN-con1, comprises the IFN-con1 molecule is combined with peg molecule (PEG12000) at the N-end.
On the other hand, the PEGization protein that the inventive method is produced is that polyalkylene glycol moiety directly is connected with protein portion, there is not spacer group to exist, do not produce any malicious byproduct yet. comprise G-CSF and total Interferon, rabbit as herein described among the embodiment. for the colony of PEGization G-CSF protein molecule, wherein polyalkylene glycol moiety is directly to be coupled to (but might not be the colony of the G-CSF molecule of the terminal PEGization of N-) on the G-CSF protein portion, and the standard reductive alkylation reaction can be carried out in acid or nonacid environment.
A further aspect of the present invention is about above-mentioned relevant medicinal compositions. this medicinal compositions can be suitable for injection, or it is oral, act on using of lung, nasal cavity and other form. in general, be contained in medicinal compositions among the present invention and comprise the of the present invention single aggressiveness/protein connector product and the medicinal acceptable diluent that goes up of significant quantity, preservatives, solubilizing agent, emulsifying agent, adjuvant and/or carrier.Comprise various damping fluid components (as: Tris-HCl, acetate, phosphoric acid salt) in this based composition, the thinner of pH and ionic strength; Additive such as stain remover and solubilizing agent (as: Tween 80, poly sorbitol ester 80), antioxidant (as xitix, sodium metabisulfite), preservatives (as: merthiolate, phenylcarbinol) and filler (as: lactose, N.F,USP MANNITOL); These materials are mixed polymer molecule such as poly(lactic acid) (polylacticacid), in the particulate state goods that polyoxyethylene glycol acid etc. is made or mix in the liposome. these compositions may influence the proteinic physical condition stability of the terminal chemically modified of N-of the present invention, removing speed in release rate in vivo and the body. for example referring to Remington ' s " pharmacology " the 18th edition.(1990, Mack publishing company., Easton, PA18042) pp.1435-1712. this paper quotes for your guidance.
The present invention has an aspect to relate to the treatment and the production method of medicine again. use that polymkeric substance/G-CSF connector that the present invention produces (or have natural G-CSF the active analogue of short hemopoietic) relaxes or the characteristic feature of the symptom nursed one's health is, going down of hematopoiesis or immunologic function, and the minimizing of the neutrophil leucocyte number of more specifically saying so. these symptoms are perhaps because (for example chemotherapy or radiotherapy) causes in other lysis of treatment. this also may be owing to suffer from infectious diseases, such as bacterium, virus, fungi or some other catch. for example, because septicemia due to the infectation of bacteria.Perhaps, this symptom is caused by heredity or environmental factors, reduces disease or leukemia as the severe chronic neutrophilic granulocyte. and age factor is also very important, and in presbyatrics, patient's neutrophil number can reduce or the neutrophil reactivity reduces.Some these class symptoms are seen Filgrastim (r-met Hu G-CSF) in clinical Practice, Morstyn, G. reaching T.M.Dexter compiles., Marcel Dedder Inc., N.Y. (1993), pp.351. some other research is few through using that polymer of the present invention/G-CSF connector relaxes and the symptom of regulating also has the minimizing of lipid in the blood (or cholesterol), and some cardiovascular symptoms are because G-CSF can induce the generation plasminogen activator.Up to now, the enable mode of G-CSF (or analogue) in these situations is also not fully aware of.The interpolation of water-soluble polymers molecule (as polyoxyethylene glycol) bring benefit can for the patient use, because the G-CSF frequency injection that bioactive postpone retention can allow each course of treatment is still less.
In general, be the symptom of those application of interference elements but use the symptom that polymkeric substance/total Interferon, rabbit can be alleviated and nurse one's health that the present invention produces, comprise cell generation disorders, virus infection and autoimmunity disorder are as comprehensive angiosclerosis.With reference to McManus Balmer, DICP, " pharmacological agent yearbook " 24:761-767 (1990) (application of the modifying factor of biologically active in cancer therapy: look back. first part, Interferon, rabbit). method and composition thereof with total interferon therapy cell generation disorders can be referring to disclosed PCT WO92/06707 on April 30th, 1992, this paper quotes for your guidance. and for example, the total interferon molecule of the PEGization that the available the present invention of hepatitis (A, B, C, D, E type) produces is treated.Prove in the following embodiments that external the total interferon activity of chemically modified is 20%. of the total Interferon, rabbit non-chemically modified
Above-mentioned various molecules, owing to carried out further research, thereby the data of used suitable dose level when having obtained the treatment of symptoms different among the relevant different patient. those of ordinary skill is being considered treatment plan, after patient age and the healthy state, can determine proper dosage. in general, should between every kg body weight 0.01 μ g to 100 μ g, (only calculate the weight of protein portion, not have calculational chemistry to modify the weight of part) for injection or perfusion dosage.
The following examples will be mentioned each side more than will illustrating. in embodiment 1, the G-CSF by the terminal PEGization of N-compares with the G-CSF of 35 Methionins or the single PEGization of 41 Methionins (being met+174 amino acid G-CSF variant) and confirms the former advantage.Standard reductive alkylation reaction in the terminal PEGization G-CSF of N-process has been described among the embodiment 2.Present method can prepare the goods of the basic homogeneous of the terminal PEGization G-CSF of N-. the standard reductive alkylation reaction in the terminal PEGization of total Interferon, rabbit N-has been discussed among the embodiment 3.
Embodiment 1
A. recombinant human met-G-CSF preparation
Recombinant human met-G-CSF (this paper is sometimes referred to as " rh-G-CSF " or " r-met-hu-G-CSF ") is according to the Souza patent, U.S. Patent No., 4,810,643 (this paper quotes for your guidance). the rhG-CSF that method is share be from E.coliIts aminoacid sequence of recombination expression product (by dna sequence encoding) shown in following (SEQ.ID.NO.1 and 2):
ATG?ACT?CCA?TTA?GGT?CCT?GCT?TCT?TCT?CTG?CCG?CAA?AGC?TTT?CTG
M T P L G P A S S L P Q S F L
CTG?AAA?TGT?CTG?GAA?CAG?GTT?CGT?AAA?ATC?CAG?GGT?GAC?GGT?GCT
L K C L E Q V R K I Q G D G A
GCA?CTG?CAA?GAA?AAA?CTG?TGC?GCT?ACT?TAC?AAA?CTG?TGC?CAT?CCG
A L Q E K L C A T Y K L C H P
GAA?GAG?CTG?GTA?CTG?CTG?GGT?CAT?TCT?CTT?GGG?ATC?CCG?TGG?GCT
E E L V L L G H S L G I P W A
CCG?CTG?TCT?TCT?TGT?CCA?TCT?CAA?GCT?CTT?CAG?CTG?GCT?GGT?TGT
P L S S C P S Q A L Q L A G C
CTG?TCT?CAA?CTG?CAT?TCT?GGT?CTG?TTC?CTG?TAT?CAG?GGT?CTT?CTG
L S Q L H S G L F L Y Q G L L
CAA?GCT?CTG?GAA?GGT?ATC?TCT?CCG?GAA?CTG?GGT?CCG?ACT?CTG?GAC
Q A L E G I S P E L G P T L D
ACT?CTG?CAG?CTA?GAT?GTA?GCT?GAC?TTT?GCT?ACT?ACT?ATT?TGG?CAA
T L Q L D V A D F A T T I W Q
CAG?ATG?GAA?GAG?CTC?GGT?ATG?GCA?CCA?GCT?CTG?CAA?CCG?ACT?CAA
Q M E E L G M A P A L Q P T Q
GGT?GCT?ATG?CCG?GCA?TTC?GCT?TCT?GCA?TTC?CAG?CGT?CGT?GCA?GGA
G A M P A F A S A F Q R R A G
GGT?GTA?CTG?GTT?GCT?TCT?CAT?CTG?CAA?TCT?TTC?CTG?GAA?GTATCT
G V L V A S H L Q S F L E V S
TAC?CGT?GTT?CTG?CGT?CAT?CTG?GCT?CAG?CCG?TAA?TAG
Y R V L R H L A Q P * *
(this also is the composition that is used for the non-PEGization of control animal). as selection, also can select for use the Neupogen on the market to carry out following PEGization reaction (this paper quotes its package insert for your guidance).
The preparation of the G-CSF of B.PEGization
The N-bicine N-of 100mM pH8.0, include the solution of the above-mentioned rh-G-CSF of 10mg/ml, joining molecular-weight average is (carboxylic methoxy polyoxyethylene glycol N-hydroxyl succinyl-ester) (Union Carbide) among the 6000 daltonian solid-state SCM-MPEG. the SCM-MPEG is here Duoed 1.5 moles than rh-G-CSF. after stirring 1 hour gently, mixture is diluted to 2mg/ml with sterilized water, and pH transfers to 4.0 with dilute hydrochloric acid.Reaction is at room temperature carried out. and reaction mixture mainly by the single PEGization rh-G-CSF of three kinds of forms, form by the rh-G-CSF of some two PEGization and the rh-G-CSG of unmodified and reaction by-product (N-hydroxyl succinimide) at this moment.
The preparation of the terminal PEGization rh-G-CSF of C.N-
The rh-G-CSF of the single PEGization of three kinds of forms can be separated with ion-exchange chromatography. and reaction mixture is splined on (every milliliter of resin of 1mg protein) Pharmacza SSepharose FF post (Pharmacia XK50/30 storehouse, column volume 440ml), with the buffer A (sodium-acetate of 20mM, pH4.0) balance in addition. clean with 3 times of buffer A then to column volume. protein example is with 15 times of buffer B to column volume (20mM sodium-acetate, pH4.0,1M NaCl), its concentration gradient is carried out the linear gradient wash-out from 0-23%. and wash-out rear pillar bed is cleaned with the buffer A of 3 volumes balance again with the buffer B of equal-volume 100% again. and the flow velocity of whole process should maintain the 8ml/min. elutriant and be monitored at 280nm, with the every pipe fraction collection of 5ml. merge the cut that contains each single PEGization rh-G-CSF kind according to Figure 1A. it is concentrated with band YM1076mm film 350mL Amicon teeter column (stirred cell) that these are merged things.
To carry out sieve chromatography from the amalgamation liquid of ion-exchange chromatography, so that the protein of two PEGization is separated from the protein of single PEGization. in most cases, the mixture upper prop that contains the 5-10mg sample in the 2-5ml solution, post is 120ml Pharmacia Superdex75HR 16/60, with the sodium-acetate of the pH4.0 of 20mM with column equilibration. with 1,5ml/min flow velocity wash-out 100 minutes. with the every pipe fraction collection of 2ml. protein content is added in monitoring at the 280nm place in the elutriant.Merge the cut at different peaks and carry out next step analysis. compare the relative proportion of each place, peak output in the following table.
Table 1
Fractional yield and decorating site
Decorating site is with reference to Figure 1A fractional yield
The terminal peak 1A 3 of N-
Lys-35 peak 2A 2
Lys-41 peak 3A 1
Under this reaction conditions, tangible PEGization reaction may not can take place in 17 and 24 Methionin.
D. feature description
In order to identify the feature of each sample, analyzed from five aspects: (1) SDS-Page (Figure 1B), (2) sieve chromatography HPLC (" SECHPLC ") (Fig. 2), (3) peptide (enzyme is cut) separating spectrum analysis (Fig. 3 A, 3B and 3C), (4) external to G-CSF bioactive test (Fig. 4) and (5) in vivo (in the hamster body) to its bioactive test (Fig. 5 A and 5B).
For each sample composition, the result shows, for the terminal single PEGization G-CSF of N-, surpassed 95% by the ratio of PEGization in the sample, perhaps, remaining is the material (although limit of detection is tested in remaining being lower than in the sample) of not PEGization. as for the percentage composition separately of three kinds of single PEGization products of form (N-end, Methionin 41 and Methionin 35), the result shows, N-end and Methionin 41PEGization product have surpassed 97% of single PEGization gross product, Methionin 35 productive rates of PEGization are lower, may be because its unstable causing in tested condition.
Table 2
The per-cent of the terminal PEGization G-CSF of N-composition
Non-also property SDS PAGE SEC HPLD N-end sequencing *
The G-CSF 97.44 99.43 96.6 of single PEGization
The G-CSF 2.56 0.57 3.4 of unmodified
* the N-end sequencing of discussing below can not be thought quantitative test at this, because when carrying out the N-end sequencing, may cause peg molecule to split away off from protein molecule N-end.
Table 3
The single PEGization product per-cent of three kinds of forms
The terminal PEG-Lys35PEG-of N-Lys41PEG-
GSCF GSCF** GSCF
(RI/UV=.96)* (RI/UV=.72) (RI/UV=1.12)
Irreducibility 97.44 77.4 1100.00
SDS-PAGE
SEC?HPLC 99.43 93.38 99.96
* RI/UV is the index of refracted light and ultraviolet absorption ratio, and it is mainly used to estimate to contain in each protein molecule the molecule number of polyoxyethylene glycol.The index of the ultraviolet absorption of the refraction of application peg molecule and reflection protein molecule is from SEC HPLC data computation.
This form G-CSF of * is unstable under test condition.
Method
1. SDS-PAGEThat .SDS-PAGE use is ISS Daiichi PureChemicals, Co., Tokyo, little glue of the irreducibility 4~20% that Japan produces, and with coomassie brilliant blue staining. gel is scanned with molecule dynamic densitometer (molecularDynamics Densitometer with Image Quant). and the result: .1 swimming lane shown in Figure 1B is (on one side left hand is that a standard molecular weight albumen (Novex Mork 12 molecular weight standard product) .2 road is 3 μ g rh-G-CSF standards; 3 roads are last sample 10 μ gSCM-PEG-GCSF reaction mixture electrophoresis result; That 4 Dao Neijia is the G-CSF of the terminal single PEGization of 10 μ gN-; Be that 10 μ g are from the terminal met number of N-, the G-CSF of the 35th the single PEGization of lysine residue in 5 roads; 6 roads are 10 μ g from the G-CSF. of the 41st the single PEGization of Methionin of N end methionine(Met) from figure as can be seen, contain the single PEGization product of N-end in 3 roads, and demonstrate the wall scroll band.
2. Sieve chromatography-high pressure liquid chromatography
What SEC-HPLC used is Biosep SEC 3000 posts, carries out in water HPLC system, and uses the 100mM sodium phosphate, under the pH6.9 condition, with 1ml/min flow velocity wash-out 20min.The signal at monitoring 280nm place. result: as shown in Figure 2, line " C ", because only contain the rh-G-CSF of the terminal single PEGization of N-, so have only a peak, line " D " (Methionin 35 single PEGization products) is identical with " E " (Methionin 41 single PEGization products) situation. this shows that also single PEGization G-CSF is pure basically in different collection tubes.
3. The peptase cutting is from collection of illustrative plates. use following method, (being called " Mono-PEG-1 ", " Mono-PEG-2 " and Mono-PEG-3 ") is analyzed to three kinds of samples.(a) the single PEGization G-CSF aliquot sample of standard reductive alkylation reaction .500 μ g is carried out rapid vacuum drying, it is mixed with 1mg/950 μ l concentration in the 0.3M Tris-HCl that contains 6M Guanidinium hydrochloride and 1mM EDTA, add iodoacetic acid in the pH of buffer 8.4. sample and carry out the S-carboxymethylation, and 37 ℃ of incubation reaction 20 minutes. sample uses Sephadex G-25 fast rotational albumen sepn post (Quick Spin Protein Columns) to carry out desalting treatment then, back exchange buffering liquid. behind desalination and exchange buffering liquid, sample concentration is diluted to 0.5mg/ml. (b) protein restriction endonuclease SV8 digestion with the damping fluid that increases with it.Sample with SV8 (enzyme-to-substrate than be 1:25) 25 ℃ of digestion process 26 hours. (c) cutting of HPLC peptase is from collection of illustrative plates.The postdigestive protein Vydac C4 post (4.6 * 250mm, particle diameter 5 μ, aperture 300) of packing into carries out wash-out with the linear gradient of acetonitrile among the 0.1%TFA, through the HPLC peptide mapping.The peptide section artificially collects and is dried the usefulness of back in order to order-checking in the rearmounted rapid vacuum drying device (Speed Vac). result: compare with the reference standard sample, (i) (Fig. 3 A) is " Mono-PEG-1 " (be N-terminal single PEGization product), in the time of 57.3 minutes peak value reduce and in the time of 77.5 minutes appearance one new peak; (ii) (Fig. 3 B) is " Mono-PEG-2 ", (Methionin 35PEGization product), and the height at peak descended to some extent and a new elution peak occurred in the time of 66.3 minute in the time of 30.3 minutes; (iii) (Fig. 3 C) is " Mono-PEG-3 " (Methionin 41PEGization product), 30.3 minute the time the peak disappear, and a new elution peak appearred in the time of 66.4 minutes. these peptide sections all demonstrate significant difference in separating spectrum. it can also be seen that because some little incomplete lysates appear in small digestion difference in the both sides of 86.1 minutes peptides from figure. (d) The N-end sequencing is analyzed. each " newly " peptide section all will be identified through the N-terminal sequence analysis in the top collection of illustrative plates. dried peptide section is dissolved in 0.1%TFA, in the ABI protein sequencer, check order. for " Mono-PEG-1 " (N-terminal PEGization product), " newly " peak product of 60% (77.5 minutes time) has carried out 10 round-robin and has checked order.Initial yield 5%, the methionine residues that this means the N-end is by peg molecule. sealing. it should be noted that, resemble this initial peptide and should cause 0 initial yield, here less than 5% value may be since in the sequencing analysis process, cause peg molecule split away off from the terminal methionine(Met) of N-due to .N-terminal peptide fragment sequencing result be: M-T-P-L-G-P-A-S-S. is for " Mono-PEG-2 " (Methionin 35PEGization product), collected and located 80% of peak value cumulative volume in 66.3 minutes, and it to be carried out 9 take turns cycle sequencing. the rate of recovery of Methionin 35 is quite low, mean that PEGization occurs on 35 Methionins. and 41 the Methionin rate of recovery is the same with other amino-acid residue, illustrating that this residue modifies. the ratio of peak respective standard that peptide was located at 30.3 minutes is low with reference to figure, the peak area that peptide was located at 30.3 minutes only is 57.5% of corresponding peptides, to its sequencing result is that K-L-C-A-T-Y-K-L. is for " Mono-PEG-3 " (Methionin 41PEGization product), for the sample of having collected peak cumulative volume 80% at the peptide of 66.4 minutes wash-outs, and it is carried out 9 round-robin check order, the sequence that detects is K-L-C-A-T-Y-K-L, wherein contain 35 consistent with other residue rate of recovery with the rate of recovery of 41 lysine residue .35 position Methionins, the rate of recovery of 41 Methionin is quite low, means that PEGization takes place at this place.The result: " Mono-PEG-1 " is the terminal single PEGization product of N-; " Mono-PEG-2 " is 35 Methionin part PEGization products; " Mono-PEG-3 " is 41 Methionin PEGization products.By compare standard (non-PEGization G-CSF) and the G-CSF1 of single PEGization, 2 and 3 collection of illustrative plates, the two collection of illustrative plates N-terminal peptide peak height of " Mono-PEG-2 " as can be seen (Lys 35) and " Mono-PEG-3 " (Lys 41) all descends slightly to some extent.All mixing in the product of this explanation Methionin 35 and Methionin 41 has minor N-terminal PEG product, and perhaps the methionine(Met) of N-end has small part by PEGization.
4. External activityThis material has activity. and that Fig. 4 shows is the analyzed in vitro result.From scheming as can be seen the rhG-CSF active 68% that the terminal single PEGization product of N-has unmodified.Method: the G-CSF vitro bioassay is the mitogenesis test of share mouse 32D cell G-CSF dependency clone. cell is cultivated with the Iscoves substratum that contains 5% FBS and 20ng/ml rhG-CSF.Before adding sample, cell is with the growth medium flushing that does not contain rhG-CSF 2 times. with 48 to 0.5ng/ml concentration ranges (be equivalent to 4800~50IU/ml) the rhG-CSF typical curves of making 12 points. every duplicate samples preparation estimates to drop on 4 kinds of diluents of (1000 arrive 3000IU/ml) in the typical curve line style part in typical curve trial scope, and with in triplicate. because these samples are obviously lower at external activity, PEGization rhG-CSF sample generally dilutes less than 4~10 times. and the sample of every part 40 μ l volume or standard diluent are added in the suitable aperture of the 96 hole droplet degree plates that contain 10,000 cells/well.At 5.5% CO 2, cultivate after 48 hours for 37 ℃, every hole add 0.5 μ m Ci methyl- 3Behind H-thymus pyrimidine .18 hour, gather in the crops dull and stereotyped cell and counting, to make dose response curve (logrhG-CSF concentration is to the CPM-background) and the point that drops in the typical curve line style part scope is carried out linear regression analysis. linear equation and dilution factor with gained are proofreaied and correct the concentration of measuring unknown test sample. result: as shown in Figure 4. as can be seen from Figure 4, in three kinds of single PEGization forms, the terminal single PEGization G-CSF of N-is at the high biological activity of external demonstration.
5. Activity in vivoMensuration has also confirmed the activity of the G-CSF of the terminal PEGization of N-in the body. and mensuration is carried out to the sample of the subcutaneous shot 0.1mg/kg of Golden Hamster body weight dosage in the body. and every group of 4 animals are drawn blood through afterbody at each time point. and the blood sample of collection carried out complete blood count the same day, and calculate the white corpuscle average number. from Fig. 5 A and 5B as can be seen, after 1 day appearance effect peak at subcutaneous single injection 0.1mg/kg body weight dosage sample. and two kinds of single PEGization products (N-end and Methionin 35) demonstrate the reaction of prolongation, and (can find out from Fig. 5 B to the rhG-CSF increased activity that the proteinic reaction of Methionin 41PEGization does not demonstrate in vivo than unmodified, activity is also more weaker in fact). these results show that peg molecule can significantly change proteinic result of treatment and the proteinic benefit of PEGization also depends on decorating site adhering on the protein molecule. (the clean average area of the WBC after the single subcutaneous injection under the curve is (according to CRC standard mathematical table, 26th Ed. (Beyer, W.H., Ed.) CRC PressInc., Boca Raton, FL 1981.p.125 calculates) consistent with Lys-35 and the terminal single PEGization product of N-).
E. stability study
In addition, the N-end and the single PEGization G-CSF of the 35 Methionins stability that prepare are above studied. (it is because confirmed the extra activity of the G-CSF that it does not exceed unmodified that 41 Methionin PEGization products are not studied).Unexpectedly other form Methionin 35 single PEGization products than the G-CSF of single PEGization are more stable when storage for the G-CSF that studies show that the terminal PEGization of N-.Stability monitors the product cracking with SEC-HPLC and measures. and terminal PEGization G-CSF of method: N-and Methionin 35 single PEGization G-CSF researchs are finished under 4 ℃ of 2 pH conditions, be pH4.0 and pH6.0,16 days each cycles. it is when making stability study be carried out .pH6.0 quickly that pH is risen to 6.0, terminal single PEGization G-CSF of the N-of above-mentioned gained and Methionin 35 single PEGization G-CSF place and contain the 20mM sodium phosphate, the 5mM sodium-acetate, 2.5% N.F,USP MANNITOL, 0.005%Tween-80, pH are to be that every milliliter of equal portions liquid of 0.25mg/ml. is stored in the 3ml aseptic injection bottle to the protein final concentration in 6.0 the damping fluid. each injection bottle was preserved 16 days in 4 ℃ and 29 ℃.Analyze its stability if draw by SEC-HPLC. measuring result afterwards is consistent (being determined by visual inspection) with initial measuring result (time 0), and then sample is considered to stable in that time.
Result: shown in Fig. 6 A-6C.
(a) compare under 4 ℃ of pH6.0 conditions.Fig. 6 A shows pH6.0, and the SEC-HPLC of the terminal single PEGization G-CSF of N-after through the certain hour section schemes under 4 ℃ of conditions; Fig. 6 B is depicted as Methionin 35 single PEGization G-CSF at pH6.0, under 4 ℃ of conditions through the figure of the SEC-HPLC after the certain hour section. have a kind of explanation to think that in the lysate of Methionin 35PEGization product, the molecular weight that has the just in time G-CSF with unmodified is close.
(b) pH4.0, renewal .pH4.0 under 4 ℃ of conditions, the control condition that provides under 4 ℃ of conditions is the condition of a quite stable, the terminal PEGization G-CSF of N-does not degrade under this condition.For Methionin 35PEGization product, the degraded of product still takes place, but its speed is much slow.
(c) pH4.0, stability under 4 ℃ of conditions is relatively. and Fig. 6 C shows under these conditions, during time limit time expand, the SEC-HPLC figure of the single PEGization product of G-CSSF. from figure as can be seen, at pH6.0, under 4 ℃ of conditions, the Methionin 35 of PEGization when 16 days or 35 days go the increase of PEG level not to be higher than 6 days the time finding level (seeing Fig. 6 B). after this means that PEGization level (unstable) has 6 days, keep under this condition becoming always.
Embodiment 2
Present embodiment has been stated a kind of method of colony of the homogeneous basically that utilizes standard reductive alkylation to react to prepare single PEGization G-CSF, characterized with this colony. the described reorganization of embodiment G-CSF. is as can be seen on this has used, this method not only has superiority aspect the protein of the terminal chemically modified of preparation N-, and the amine key in this standard reductive alkylation reaction process produces more stable in fact product, shown than big-difference as aggregation extent when storing.
A. The single methoxy polyoxyethylene glycol-GCSF that adheres on the terminal alpha-amino group residue of N-connects The preparation of thing.
Preparation rhG-CSF reaction soln (1ml, concentration is 5mg/ml, described in top embodiment) includes the 100mM sodium phosphate, and pH5.0 also contains 20mM NaCNBH 3, it is fully stirred freezing (4 ℃) after, add mole number and exceed 5 times methoxy polyethylene glycol aldehyde (MPEG) (molecular-weight average is 6kDa). reaction mixture continues to stir under uniform temp.
Proteinic degree of modification is come its monitoring with SEC-HPLC in the reaction process, and what SEC-HPLC used is Bio-Sil SEC 250-5 post (BIO-RAD), under the pH6.8 condition, uses 0.05M NaH 2PO 4, 0.05M Na 2HPO 4, 0.15M NaCI, 0.01MNaN 3, damping fluid carries out wash-out with the 1ml/min flow velocity.
SEC HPLC analytical results shows after 10 hours, existing 92% protein transduction becomes the mono-MPEG-GCSF derivative. and this is as can be seen from Figure 7, wherein write down protein concn (recording) with light absorption ratio at the A280 place, the elution peak that has shown the single PEGization G-CSF product that in the time of 8.72 minutes, occurs, the less elution peak of the G-CSF that does not react that occurred at 9.78 minutes.
Fig. 8 has shown the peak with the N-hydroxyl succinyl-fat gained of MPEG as a comparison. its molecular weight also is that 6kDa. is from scheming as can be seen, in reaction mixture, have: tri-MPEG-GCSF connector (peak is takeed on all at 7.25 minutes), di-MPEG-GCSF connector (peak value is at 7.62min), mono-MPEG-GCSF connector (peak value is at 9.87min).
At 10 hours time points, 92% protein was converted to single PEGization product, and the pH of its reaction mixture transfers to pH4.0 with 100mM HCl, and with 1mM HCl reaction mixture was diluted 5 times.
The mono-MPEG-GCSF derivative is that 4.0 equilibrated HiLoad, 16/10 S Sepharose HP post (Pharmacia) carries out purifying with the sodium-acetate buffer pH that ion exchange chromatography share with 20mM.Reaction mixture is with 1ml/min flow velocity dress post, unreacted MPEG carries out wash-out with 3 times of same buffer to column volume. and carry out 400 minutes linear gradient elution then, 20mM sodium-acetate concentration is from 0%-45%, pH4.0, include 1M NaCl, at 4 ℃ of elute proteins-polymkeric substance connector.
The collection tube that will contain the mono-MPEG-GCSF derivative merges, and concentrates and filtration sterilization.
Modify rh-G-CSF and the various forms mono-MPEG-GCSF connector that obtains prepares with similarity method with the MPEG aldehyde of different molecular-weight average (12,20 and 25kDa).
The analysis of B. single PEGization G-CSF
1. molecular weight
Utilize SDS-PAGE, gel-filtration, ground substance assistant laser is resolved mass spectroscopy (matrix assisted laser desorption), and the equilibrium centrifugation method is measured the molecular weight of single PEGization connector. and the result is as shown in table 4 below.
Table 4
N-end alkyl Mono-MPEG-GCSF connector molecular weight
The gel-filtration mass spectrum that connector is estimated is surveyed super centrifugal survey
Molecule measuring weight molecule amount molecular weight
MPEG-
(6kDa)- 24800 53024 24737 25548
G-CSF
MPEG-
(12kDa)- 30800 124343 30703 29711
GCSF
MPEG-
(20kDa)- 38800 221876 38577 38196
GCSF
MPEG-
(25kDa)- 43800 333266 N/D N/D
GCSF
The terminal mono-MPEG-GCSF connector of the N-of preparation structure is cut the figure spectrometry with matter sequential analysis of N-terminal protein and peptase and is confirmed that the terminal bromize fluoride crack with sulphur aminoacyl residue of .N-causes removing of peg molecule.
2. Biological activity
The external biological of PEGization MPEG-GCSF connector is active to stimulate the mouse medullary cell right through measuring 3The absorption of H thymus pyrimidine is measured.
Biological activity is through measuring measuring its total leukocyte number behind MPEG-GCSF connector or rhG-CSF (100mg/ gram body weight dosage) the subcutaneous injection hamster in the body.Compare with the G-CSF of unmodified, the bioactive calculating of PEGization G-CSF is to deduct the vehicle Control area under curve and the expression of the relative reactivity of the .MPEG-GCSF derivative that obtains is described with its percentage activity of comparing with the G-CSF of unmodified with area under the WB/ time curve.
As shown in Figure 9, shown the total leukocyte number reaction of the mono-N-terminal M PEG-GCSF connector that the MPEG aldehyde with different molecular weight (6kDa, 12kDa and 20kDa) is made through the reductibility alkylation reaction. from figure as can be seen, the equal induced reaction of all single PEGization products. except the PEG of 12kDa white corpuscle number after second day white corpuscle number is than the effect of 20kDa PEG product is big slightly, used molecular weight polyethylene glycol is big more, and the white corpuscle number of acquisition can be many more.
3. stability study
Compared extent of polymerization with the terminal PEGization G-CSF of N-of two kinds of different chemical processes (referring to the standard reductive alkylation reaction of amine and acid amides here) preparation. unexpectedly, find that the terminal PEGization G-CSF of the N-that forms with the amine key is much more stable than the terminal PEGization G-CSF of the N-that forms with amido linkage (the NHS method described in the embodiment 1).
Method: the terminal PEGization G-CSF of the N-of two kinds of forms product places the 10mMNaO of pH4.0 MeIn, wherein contain 5% sorbyl alcohol, the protein molecule final concentration is to contain 1mg protein .G-CSF in every ml solution all with PEG6000PEGization. embodiment 1 is pressed in the preparation of amido linkage connector, amine key connector preparation is undertaken by embodiment 2. and duplicate samples such as 6 of every kind of form are preserved 8 all .8 after week at 45 ℃, measure aggregation extent with sieve chromatography and ion-exchange chromatography.
The result: the result shows that standard reductive alkylation reaction product of the present invention is much more superior than acetylate; because; it is shocking; product is after 8 weeks under the temperature condition that raises, and the former aggregation extent is more much smaller than the latter. and following table is that accumulative percentage ratio does not take place after sieve chromatography (SEC) or ion-exchange chromatography (IE) analysis two kinds of form products separately:
Table 5
45 ℃ of following 8 all % main peak SEC/IE of sample
Amine key product 82%/84%
Amido linkage product 37%/65%*
* this value is higher relatively is because ion-exchange chromatography can not carry out the exhaustive analysis of aggregation extent.
Embodiment 3
This embodiment describes the total Interferon, rabbit of chemically modified. and more particularly, this embodiment has described a kind of method of colony of the homogeneous basically for preparing single PEGization IFN-con1, and the characterized of this colony.
Should be noted that; though that use in the present embodiment is IFN-con1; although but above-mentioned arbitrary total Interferon, rabbit all can be by chemically modified. used polyoxyethylene glycol to modify in the present embodiment; but resembling this chemically modified can carry out with above-mentioned arbitrary water-soluble polymers. turn usefulness into for PEG; though that use in the present embodiment is PEG12000; but other any type of water-soluble PEG all can use (use herein PEG12000 be for be easy to handle and convenient). same; a variety of chemical modification methods (such as acetylization reaction) are also arranged here; but for selective N-terminal chemically modified (as the terminal PEGization reaction of N-), had better be with the reductibility reaction described in this embodiment.
A. the preparation of total Interferon, rabbit
Interferon, rabbit IFN-α con1 (refers to that here IFN-con1 (can be referring to U.S. Patent No. 4,695, it is better than description among 623 Fig. 2 (quote its in full for your guidance) the single PEGization of preparation and has Interferon, rabbit .IFN-con1 and express exogenous DNA and produce in bacterium, and its N-end has a methionyl residue.
B. have the PEGization of Interferon, rabbit
It is 100mM that IFN-con1 solution (3.45mg/ml contains 35.25% N-end closure form) is dissolved in sodium phosphate concentration, and pH4.0 includes 20mM NaCNBH 3Solution in, abundant mixing after 4 ℃ of coolings adds the methoxy polyethylene glycol aldehyde (MPEG) (molecular-weight average is 12kDa) that exceeds 8 times of molar weights.
Proteinic degree of modification is monitored with reversed-phase HPLC in reaction process, and HPLC adorns post with poly (vinylbenzene/Vinylstyrene), as PLRP-S (PL SeperationSciences Polymer Labaratories).
After 10 hours, the reversed-phase HPLC analytical results shows that the protein transduction that 80% N-end has untight α amino becomes the MPEG-IFN-con1 derivative.
At 10 hours time points, 5 times of reaction mixture dilute with waters, the purifying of mono-MPEG-IFN-con1 derivative is finished with ion exchange chromatography, its used post is a Hiload16/10 S Sepharose HP post (Pharmacia), with the sodium-acetate buffer pH4.0 of 20mM balance in addition. reaction mixture is packed into the flow velocity of 1ml/min in the post, unreacted MPEG aldehyde with 3 times to the same buffer of column volume wash-out in addition. under 4 ℃ of conditions, carry out the wash-out of protein-polymer connector molecule then, 20mM sodium-acetate buffer with 0%~75% carried out linear elution 420 minutes. and pH of buffer is 4.0, contains 1M NaCl.
Merge the cut that contains the mono-MPEG-IFN-con1 derivative, after concentrating, refilter sterilization.
The analysis of the total Interferon, rabbit of C. single PEGization
1. homogeneity
The mono-MPEG-IFN-con1 connector homogeneity of purifying is detected by SDS-PAGE, and what SDS-PAGE used is the prefabricated gradient glue (Integrated Separation System) of 10-20% or 4-20%. and gel shows that mainly being with at molecular weight is the 35kDa place.
What the effective radius of various forms mono-MPEG-IFN-con1 (hydrodynamic radius) was measured usefulness is Superose 6HR 10/30 (Pharmacia) gel-filtration column. at the 280nm place through determination of uv absorption protein .BIO-RAD gel filtration standards as the globular proteins molecular weight marker.
The terminal mono-MPEG-I FN-con1 of the N-of purifying connector structure adopts order-checking of N-terminal protein matter and peptase to cut collection of illustrative plates and is confirmed.
Here must be noted that and contain some N-end closure materials in these IFN-con1 goods, yet PEGization does not take place in them., the material of PEGization is even to be the terminal single PEGization of N-. thereby, in this case, can consider can be with other method with end closure and untight product separately, as with ion exchange chromatography or molecular sieve analytical method.
2. Biological activity
Mono~MPEG-IFN con1 connector external biological activity is to determine through measuring its antiviral biological activity in people (Hela) cell through the external biological of measuring the .mono-MPEG-IFN con1 connector that its antiviral activity measures is active.
Find that (U/mg protein is that unmodified IFN-con1 active 20%. is as foregoing PEGization G-CSF to mono-MPEG (12kDa)-IFN-con1 connector external biological activity, though analyzed in vitro has certain effect to understanding biological activity, but because characteristic slowly discharges, the chemically modified protein matter activity that often records is very low. biological activity is than external height in the body.
D.N-end closure molecule is removed the total Interferon, rabbit of back chemically modified.
Foregoing IFN-con1 also carries out standard reductive alkylation reaction of the present invention after removing N-end closure molecular moiety wherein in advance. described in the above standard reductive alkylation reaction.Used two kinds of molecules of PEG12000 and PEG20000 in the above in the described reductive alkylation process on glycopeptides.
The apparent molecular weight of this molecule is as follows
The SDS-PAG that the connector gel-filtration records records
The apparent molecular weight of apparent molecular weight
monoMPEG(12kDa) 104.0kDa 35.6kDa
IFN-con1
monoMPEG(20kDa) 175.1kDa 55.4kDa
IFN-con1
3 peaks appear among the FPLC ion-exchange chromatogram analysis result of IFN-con1 20kDa PEG connector:
MonoMPEG-IFN-con1: 66% (being eluted to 265.93ml) that accounts for the total area.
Protein aggregate (aggregate) and oligomerization MPEG-IFN-con1 connector: account for the total area 24% (being eluted to 238.42ml) and
Unreacted IFN-con1: account for 10% the total area (being eluted to 328.77ml).
This condition is not further optimized as yet, and available chromatogram or other method are further separated the material of single PEGization.
Although described the present invention, should understand for a person skilled in the art and can change and revise with preferred embodiment.Therefore, in appending claims, attempt to cover all and drop on equivalent variations in the desired scope of the invention.
Sequence table
(1) general information:
(i) applicant: AMGEN INC
The (ii) protein composition and the method for the terminal chemically modified of invention exercise question: N-.
(iii) sequence number: 2
(iv) contact address:
(A) address: Amgen Inc.
(B) street: 1840 Dehavilland Drive
(C) city: Thousand Daks
(D) state: California
(E) country: USA
(F) postal code: 91320
(v) computer-reader form:
(A) medium for storing: diskette
(B) computer: IBM PC compatible
(C) operating system: PC-DOS/MS-DOS
(D) software: PatentIn Release #1.0, #1.25. version
(vi) current application materials:
(A) application number:
(B) applying date:
(C) classification:
(viii) proxy/proxy information:
(A) name: Pessin, Karol M.
(B) reference/summary number: A-286
(2) SEQ ID NO:1 information:
(i) sequence signature:
(A) length: 531 base pairs
(B) type: nucleic acid
(C) chain: strand
(D) topology feature: linear
(ii) molecule type: cDNA
(xi) sequence description: SEQ ID NO:1:
Figure A200810127675D00381
(2) SEQ ID NO:2 information:
(i) sequence signature:
(A) length: 175 amino acid
(B) type: amino acid
(C) chain: strand
(D) topology feature: linear
(ii) molecule type: protein
(xi) sequence description: SEQ ID NO:2:
Figure A200810127675D00382
Figure A200810127675D00391

Claims (65)

1. the total Interferon, rabbit of chemically modified partly is connected at least one water-soluble polymers by total ifn protein and forms on partly.
2. the total Interferon, rabbit of the chemically modified of claim 1, wherein said total Interferon, rabbit partly is selected from IFN-con1, IFN-con2 and IFN-con3.
3. the total Interferon, rabbit of the chemically modified of claim 2, wherein said water-soluble polymers be medicinal acceptable.
4. the total Interferon, rabbit of the chemically modified of claim 1, wherein said water-soluble polymers is selected from: dextran, poly (n-V-Pyrol RC), polyoxyethylene glycol, propylene glycol homopolymer, polyoxytrimethylene/ethylene oxide interpolymer, polyoxy ethylization polyvalent alcohol and polyvinyl alcohol.
5. according to the total Interferon, rabbit of the chemically modified of claim 4, wherein said water-soluble polymers partly is a polyoxyethylene glycol.
6. according to the total Interferon, rabbit of the chemically modified of claim 1, wherein said water-soluble polymers part need not be directly connected on the said total Interferon, rabbit part by other linking group.
7. the total Interferon, rabbit of a chemically modified is connected at least one polyalkylene glycol moiety by IFN-con1 and forms.
8.PEG the total Interferon, rabbit of changing.
9. the method for an attached water soluble polymer on total Interferon, rabbit, wherein said water-soluble polymers has single reaction aldehyde radical, and said method comprises:
(a) under the standard reductive alkylation condition,, make total Interferon, rabbit partly and the water-soluble polymers partial reaction enough acid with selectively activate under the pH value of said total Interferon, rabbit part N-terminal alpha-amino group group;
(b) obtain reaction product and
(c) reaction product isolated in the part that can randomly never react.
10. the method for claim 9, wherein said polymkeric substance be medicinal acceptable.
11. the method for claim 9, wherein said water-soluble polymers is selected from: dextran, poly (n-V-Pyrol RC), polyoxyethylene glycol, propylene glycol homopolymer, polyoxytrimethylene/ethylene oxide interpolymer, polyoxy ethylization polyvalent alcohol and polyvinyl alcohol.
12. the method for claim 11, wherein said polymkeric substance is a polyoxyethylene glycol.
13. the method for claim 9, wherein said standard reductive alkylation reaction relates to uses the reductive agent that is selected from sodium borohydride, sodium cyanoborohydride, boric acid dimethylamine, boric acid Trimethylamine 99 and boric acid pyridine.
14. a method of adhering to peg molecule on total interferon molecule, wherein said peg molecule has single reaction aldehyde radical, and said method comprises:
(a) under the standard reductive alkylation condition, under the pH value of the terminal alpha-amino group group of said total Interferon, rabbit, said total Interferon, rabbit and said peg molecule are reacted with selectively activate enough acid;
(b) the total Interferon, rabbit that obtains PEGization with
(c) the total Interferon, rabbit of PEGization can randomly never take place to isolate in the total Interferon, rabbit of PEGization.
15. the method for claim 14, wherein said peg molecule have the molecular weight of about 2kDa to about 100kDa.
16. the PEGization of being produced with the method for claim 14 has the Interferon, rabbit product.
17. the goods of the basic homogeneous of the total Interferon, rabbit of single PEGization.
18. the goods of claim 17 comprise the total Interferon, rabbit of about 90% single PEGization and the total Interferon, rabbit of about 10% not PEGization.
19. medicinal compositions, the goods of homogeneous basically that comprise the total Interferon, rabbit of (a) single PEGization, the total Interferon, rabbit of said single PEGization is connected to total Interferon, rabbit by a polyalkylene glycol moiety and partly goes up and forms, and this connects and passes through the amine key also only at its N-terminal; (b) be less than the total interferon molecule of 5% not PEGization; (c) a kind of medicinal acceptable diluent, adjuvant or carrier gone up.
20. a method for preparing the terminal single PEGization polypeptide of N-, it may further comprise the steps:
(a) make polypeptide that its N-end has α amino in aqueous medium, be enough in standard reductive alkylation and pH acidity react under the condition of selectivity activation α amino with water-soluble polyethylene glycol with an aldehyde radical and
(b) polypeptide of the terminal single Pegylation of separation N-from reaction mixture.
21. the method for claim 20, wherein the molecular weight of employed polyoxyethylene glycol is about 2kDa to 100kDa.
22. the method for claim 21, wherein the molecular weight of employed polyoxyethylene glycol is about 6kDa to 25kDa.
23. each method of claim 20-22, wherein employed polyoxyethylene glycol is a methoxy poly (ethylene glycol) aldehyde.
24. each method of claim 20-23, the reductive agent that wherein uses in standard reductive alkylation is sodium borohydride or sodium cyanoborohydride.
25. each method of claim 20-24, wherein employed polypeptide is total interferon-alpha.
26. the method for claim 25, wherein employed total interferon-alpha is the methionine(Met) part-1 of its N-terminal.
27. each method of claim 20-26, wherein said separating step (b) comprises purifying.
28. the method for claim 27, wherein said purifying comprises the ion exchange chromatography of described reaction mixture and sieve chromatography.
29.N-terminal single Pegylation has interferon-alpha, it obtains by each method of claim 20-28.
30. a medicinal compositions, it comprises the total interferon-alpha of the terminal single Pegylation of N-of claim 29.
31. goods, it comprises the single polymkeric substance/proteic conjugate of significant quantity, this conjugate is made by the hematopoietic proteins with the amino reactive group of one or more effective ε, the polyethylene glycol polymer of wherein said single polymkeric substance/proteic conjugate partly is positioned at N-terminal but not on ε amino, and described polyethylene glycol polymer part is puted together by α amino; And wherein said single polymkeric substance/protein conjugate prolongs with respect to biological activity in the non-body of puting together hematopoietic proteins.
32. the goods of claim 31, wherein said goods comprise the single polymkeric substance/proteic conjugate greater than 80%.
33. the goods of claim 31, wherein said goods comprise at least 90% single polymkeric substance/protein conjugate.
34. the goods of claim 31, wherein said goods comprise greater than 95% single polymkeric substance/protein conjugate.
35. the goods of claim 31, wherein said goods comprise at least 99% single polymkeric substance/protein conjugate.
36. the goods of single Pegylation hematopoietic proteins, described single Pegylation hematopoietic proteins is made by the hematopoietic proteins with the amino reactive group of one or more effective ε, and wherein said polyethylene glycol polymer part mainly is conjugated in the N-terminal of described hematopoietic proteins and puts together by α amino; And wherein said single Pegylation hematopoietic proteins prolongs with respect to biological activity in the non-body of puting together hematopoietic proteins.
37. the hematopoietic proteins goods of claim 31 or 36, the about 2kDa of the molecular weight of wherein said polyoxyethylene glycol is to about 100kDa.
38. the hematopoietic proteins goods of claim 37, the about 6kDa of the molecular weight of wherein said polyoxyethylene glycol.
39. the hematopoietic proteins goods of claim 37, the about 12kDa of the molecular weight of wherein said polyoxyethylene glycol.
40. the hematopoietic proteins goods of claim 37, the about 20kDa of the molecular weight of wherein said polyoxyethylene glycol.
41. the hematopoietic proteins goods of claim 37, the about 25kDa of the molecular weight of wherein said polyoxyethylene glycol.
42. a medicinal compositions, it comprises (a) claim 31,32,33,34,35,36,38,39,40 or 41 goods and (b) pharmaceutically acceptable thinner, carrier or auxiliary.
43. a medicinal compositions, it comprises the goods of (a) claim 37 and (b) pharmaceutically acceptable thinner, carrier or auxiliary.
44.N-the goods of homogeneous basically of the G-CSF of terminal chemically modified or its analogue, optional being present in medicinal upward acceptable diluent, carrier or the adjuvant.
45. the goods of claim 44, wherein said G-CSF carries out chemically modified with the chemical substance that is selected from dextran, poly (n-V-Pyrol RC), polyoxyethylene glycol, propylene glycol homopolymer, polyoxytrimethylene/ethylene oxide interpolymer, polyoxy ethylization polyvalent alcohol and polyvinyl alcohol.
46. the goods of claim 45, wherein said G-CSF or its analogue carry out chemically modified with polyoxyethylene glycol.
47. the goods of claim 46, wherein said polyalkylene glycol moiety partly is connected with G-CSF by amido linkage.
48. the goods of claim 47, wherein the peg molecule that connects by amido linkage is a polyethylene glycol aldehyde.
49. each goods of claim 46 to 48, wherein said G-CSF or its analogue are single Pegylation.
50. the goods of claim 46, wherein said polyoxyethylene glycol have at about 2kDa to the molecular weight between the 100kDa.
51. the goods of claim 50, wherein said polyoxyethylene glycol has about 6kDa to the molecular weight between the 25kDa.
10% the G-CSF that PEGization does not take place or its analogue are formed at the most 52. the goods of claim 44, wherein said goods are reached by the G-CSF of the terminal single PEGization of 90% N-or its analogue at least.
5% the G-CSF that PEGization does not take place or its analogue are formed at the most 53. the goods of claim 52, wherein said goods are reached by the G-CSF of the terminal single PEGization of 95% N-or its analogue at least.
54. the goods of claim 44, wherein said G-CSF has the sequence of identifying in SEQ ID NO.1.
55.N-the goods of the homogeneous basically of the G-CSF of terminal single PEGization, optional being present in medicinal upward acceptable diluent, carrier or the adjuvant, wherein: (a) said G-CSF has the aminoacid sequence of identifying in SEQ ID No.1; (b) the said G-CSF molecular weight single PEGization of polyalkylene glycol moiety that is about 12kDa.
56. a medicinal compositions comprises: (a) goods of the homogeneous basically of the G-CSF of single PEGization, the G-CSF of said single PEGization only are connected on the G-CSF part at the N-of G-CSF end by the amine key by the polyalkylene glycol moiety with the about 12kDa of molecular weight to be formed; (b) less than 5% non-PEGization G-CSF molecule and (c) medicinal acceptable diluent, adjuvant or the carrier gone up.
57. the method for treatment hematopoiesis disorders comprises any one goods of the claim 44-56 of significant quantity on the administering therapeutic.
58. one kind with the method for water-soluble polymers molecule attached on protein or its analogue, wherein said water-soluble polymers has single reaction aldehyde radical, and said method comprises:
(a) under the standard reductive alkylation condition, enough acid, so that the pH value that water-soluble polymers optionally is attached on the said alpha-amino group is following to protein portion and water-soluble polymers partial reaction with the said protein portion N-terminal of selectively activate alpha-amino group group; With
(b) obtain reaction product and
(c) reaction product isolated in the optional part that never reacts.
59. the method for claim 58, wherein said polymkeric substance are medicinal acceptable.
60. the method for claim 58, wherein said water-soluble polymers is selected from: dextran, poly (n-V-Pyrol RC), polyoxyethylene glycol, propylene glycol homopolymer, polyoxytrimethylene/ethylene oxide copolymer, polyoxy ethylization polyvalent alcohol and polyvinyl alcohol.
61. the method for claim 60, wherein said polymkeric substance is a polyoxyethylene glycol.
62. relating to using, the method for claim 58, wherein said reductibility alkylation reaction be selected from sodium borohydride, sodium cyanoborohydride, the reductive agent of boric acid dimethylamine, boric acid Trimethylamine 99 and boric acid pyridine.
63. one kind is attached to method on the G-CSF molecule with peg molecule, wherein said peg molecule contains single reaction aldehyde radical, and said method comprises:
(a) under reductibility alkylation reaction condition,, said G-CSF and said peg molecule are reacted enough acid optionally activation under the pH value of said G-CSF N-terminal alpha-amino group group; With
(b) G-CSF that obtains PEGization with
(c) optionally from non-PEGization G-CSF, isolate PEGization G-CSF.
64. the method for claim 63, wherein said molecular weight polyethylene glycol are that about 6kDa is to about 25kDa.
65. the PEGization G-CSF product of producing with the method for claim 63.
CN2008101276757A 1994-10-12 1995-02-08 N-terminally chemically modified protein compositions and methods Expired - Lifetime CN101381409B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/321510 1994-10-12
US08/321,510 US5824784A (en) 1994-10-12 1994-10-12 N-terminally chemically modified protein compositions and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN95191454A Division CN1071760C (en) 1994-10-12 1995-02-08 N-terminally chemically modified protein compositions and methods

Publications (2)

Publication Number Publication Date
CN101381409A true CN101381409A (en) 2009-03-11
CN101381409B CN101381409B (en) 2013-03-27

Family

ID=23250903

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2008101276757A Expired - Lifetime CN101381409B (en) 1994-10-12 1995-02-08 N-terminally chemically modified protein compositions and methods
CN95191454A Expired - Lifetime CN1071760C (en) 1994-10-12 1995-02-08 N-terminally chemically modified protein compositions and methods
CNB001309749A Expired - Lifetime CN1229388C (en) 1994-10-12 1995-02-08 N-terminal modified protein compositions and methods therefor
CNA2005101137680A Pending CN1896103A (en) 1994-10-12 1995-02-08 N-terminally monopegylated polypeptides and process for their preparation

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN95191454A Expired - Lifetime CN1071760C (en) 1994-10-12 1995-02-08 N-terminally chemically modified protein compositions and methods
CNB001309749A Expired - Lifetime CN1229388C (en) 1994-10-12 1995-02-08 N-terminal modified protein compositions and methods therefor
CNA2005101137680A Pending CN1896103A (en) 1994-10-12 1995-02-08 N-terminally monopegylated polypeptides and process for their preparation

Country Status (20)

Country Link
US (7) US5824784A (en)
EP (5) EP2392594A1 (en)
JP (8) JP3177251B2 (en)
KR (2) KR100248111B1 (en)
CN (4) CN101381409B (en)
AT (2) ATE179991T1 (en)
CA (3) CA2472085A1 (en)
DE (3) DE10299044I1 (en)
DK (1) DK0733067T3 (en)
ES (2) ES2131811T3 (en)
GR (1) GR3030526T3 (en)
HK (2) HK1008787A1 (en)
IL (3) IL112585A (en)
LU (1) LU91006I2 (en)
MX (1) MX9602259A (en)
NL (1) NL300106I2 (en)
NZ (1) NZ281469A (en)
PT (1) PT822199E (en)
WO (1) WO1996011953A1 (en)
ZA (1) ZA951008B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026182A (en) * 2015-09-18 2018-05-11 国立大学法人宫崎大学 Long-acting adrenomedulin derivative
CN112710826A (en) * 2020-11-17 2021-04-27 北京九强生物技术股份有限公司 Coating and sealing method for improving stability of reagent
CN113214328A (en) * 2021-05-08 2021-08-06 宁波经济技术开发区弘翔生化科技有限公司 Double-aqueous-phase system and monosaccharide separation method based on double-aqueous-phase system

Families Citing this family (546)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996041813A2 (en) * 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
US6583267B2 (en) 1997-06-06 2003-06-24 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1012184B1 (en) * 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
JP4574007B2 (en) * 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム Polyol-IFN-beta complex
CZ300540B6 (en) * 1998-05-15 2009-06-10 Schering Corporation Pharmaceutical composition comprising ribavirin combined with alpha interferon for treating patients with chronic infection of hepatitis C of genotype 1
NL1009601C2 (en) * 1998-07-09 2000-01-11 Univ Utrecht Compound which can inhibit the binding of a protein to mast cells, use of the compound for the preparation of a medicament, a pharmaceutical preparation, a method of diagnosing a disease and a selection method.
WO2000004041A2 (en) * 1998-07-16 2000-01-27 Hyseq, Inc. Methods and molecules relating to cd39-like polypeptides
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
BR9915548A (en) * 1998-10-16 2001-08-14 Biogen Inc Interferon-beta fusion proteins and uses
DE69930015T2 (en) 1998-10-16 2006-10-12 Biogen Idec Ma Inc., Cambridge POLYMER CONJUGATES OF INTERFERON BETA-1A AND ITS USES
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
TWI257394B (en) 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
CA2352538A1 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR122013003013B8 (en) 1999-01-14 2021-07-06 Bolder Biotechnology Inc Monopegylated growth hormone isolated protein and method for obtaining it
ATE246202T1 (en) * 1999-01-29 2003-08-15 Hoffmann La Roche GCSF CONJUGATES
EP1369429A1 (en) * 1999-01-29 2003-12-10 F. Hoffmann-La Roche Ag GCSF conjugates
WO2000051626A1 (en) * 1999-03-01 2000-09-08 Kyowa Hakko Kogyo Co., Ltd. Chemically modified g-csf preparations
US6485718B1 (en) 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7160924B2 (en) * 2002-07-19 2007-01-09 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
ES2327606T3 (en) 2000-01-10 2009-11-02 Maxygen Holdings Ltd CONJUGATES OF G-CSF.
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US7049761B2 (en) * 2000-02-11 2006-05-23 Altair Engineering, Inc. Light tube and power supply circuit
DE60138364D1 (en) 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
DE60103940T2 (en) 2000-02-29 2005-07-28 Pfizer Products Inc., Groton Stabilized granulocyte colony stimulating factor
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001079469A2 (en) * 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
WO2001081376A2 (en) 2000-04-21 2001-11-01 Amgen Inc. Apo-ai/aii peptide derivatives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2001273387A1 (en) * 2000-07-12 2002-01-21 Gryphon Therapeutics, Inc. Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
CN1454097A (en) * 2000-09-08 2003-11-05 格莱风治疗公司 Polymer-modified synthetic proteins
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ES2367891T3 (en) * 2000-09-29 2011-11-10 Schering Corporation INTERLEUCINA-10 PEGILADA.
JP5170931B2 (en) * 2000-10-16 2013-03-27 中外製薬株式会社 PEG-modified erythropoietin
US6706289B2 (en) * 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
EP1334127A1 (en) * 2000-11-02 2003-08-13 Maxygen Aps Single-chain multimeric polypeptides
CN1321134C (en) * 2000-11-23 2007-06-13 赵剑 Hetergeneous product of bio-active protein and its preparing process
JP2004515533A (en) * 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ,インコーポレイテッド Peptide YY and peptide YY agonist for treating metabolic disorders
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
MXPA03005406A (en) * 2000-12-20 2003-09-25 Hoffmann La Roche Erythropoietin conjugates.
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
DE60227367D1 (en) * 2001-02-06 2008-08-14 Merck Patent Gmbh MODIFIED GRANULOCYTE STIMULATING FACTOR (G-CSF) WITH REDUCED IMMUNOGENITY
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
ATE432288T1 (en) 2001-02-27 2009-06-15 Maxygen Aps NEW INTERFERON BETA-LIKE MOLECULES
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
CA2445947A1 (en) * 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
RS51708B (en) 2001-05-11 2011-10-31 Amgen Inc. Peptides and related molecules that bind to tall-1
US7229810B2 (en) * 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
MXPA04000231A (en) * 2001-07-11 2004-05-04 Maxygen Holdings Ltd G-csf conjugates.
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
IL160965A0 (en) * 2001-10-05 2004-08-31 Intermune Inc Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
EP2236161A1 (en) 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
AU2002366023B2 (en) * 2001-11-19 2007-10-25 Kyowa Hakko Kirin Co., Ltd. Drug mobilizing pluripotent stem cells from tissue into peripheral blood
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002356990A1 (en) * 2001-11-20 2003-06-10 Pharmacia Corporation Chemically-modified human growth hormone conjugates
KR100480432B1 (en) * 2001-12-04 2005-04-06 선바이오(주) Conjugates of granulocyte-colony stimulating factor and polyethylene glycol derivatives
EP1461067A1 (en) * 2001-12-07 2004-09-29 Intermune, Inc. Compositions and method for treating hepatitis virus infection
DE60323936D1 (en) * 2002-01-14 2008-11-20 Gen Hospital Corp BIOABEAABLE POLYCETALES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE
WO2003061577A2 (en) * 2002-01-18 2003-07-31 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
DE60335639D1 (en) * 2002-06-14 2011-02-17 Amylin Pharmaceuticals Inc PREVENTION AND / OR TREATMENT OF COLITIS ULCEROSA WITH PYY OR PYYE3-36Ü
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
EP1534269B1 (en) * 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
JP2006508056A (en) 2002-08-28 2006-03-09 イミュネックス・コーポレーション Compositions and methods for treating cardiovascular disease
JP4764630B2 (en) 2002-09-09 2011-09-07 ネクター セラピューティックス Water-soluble polymer alkanal
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JP2004196770A (en) * 2002-10-24 2004-07-15 Effector Cell Institute Inc Agent for increasing blood level of dendritic cell precursor
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
WO2004063221A1 (en) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
RS20050501A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
RS20050502A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US7803362B2 (en) * 2003-01-24 2010-09-28 Synageva Biopharma Corp. Glycosylated interferon alpha
CN1997666A (en) * 2003-02-26 2007-07-11 印特缪恩股份有限公司 Polyethylene glycol modified interferon compositions and methods of use thereof
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP4464395B2 (en) 2003-03-05 2010-05-19 ヘイローザイム インコーポレイテッド Soluble hyaluronidase glycoprotein (sHASEGP), process for its preparation, use and pharmaceutical composition comprising it
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
BRPI0408358A (en) 2003-03-14 2006-03-21 Neose Technologies Inc branched water-soluble polymers and their conjugates
JP2006521372A (en) * 2003-03-28 2006-09-21 バイオポリメド インコーポレーテッド 1: 1 conjugate of biologically active substance and biocompatible polymer, method for producing the same, and pharmaceutical composition containing the same
US20060134736A1 (en) * 2003-03-28 2006-06-22 Jacobs John W Human growth hormone conjugated with biocompatible polymer
EP1610825A2 (en) 2003-03-31 2006-01-04 Xencor, Inc. Methods for rational pegylation of proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1613272B1 (en) * 2003-04-11 2013-12-18 Antriabio, Inc. Method for preparation of site-specific protein conjugates
DE602004025799D1 (en) 2003-04-15 2010-04-15 Glaxosmithkline Llc HUMANE IL-18 SUBSTITUTION MUTANTS AND THEIR CONJUGATES
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
EP2390262A1 (en) 2003-05-16 2011-11-30 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
CA2533702C (en) 2003-07-22 2012-05-22 Nektar Therapeutics Al, Corporation Method for preparing functionalized polymers from polymer alcohols
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US7267960B2 (en) 2003-07-25 2007-09-11 Amgen Inc. Antagonists and agonists of LDCAM and methods of use
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CN100519581C (en) 2003-08-25 2009-07-29 东丽株式会社 Interferon-beta composite
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
KR101200729B1 (en) 2003-09-17 2012-11-13 넥타르 테라퓨틱스 Multi-arm polymer prodrugs
US7642235B2 (en) * 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7230068B2 (en) 2003-10-09 2007-06-12 Ambrx, Inc. Polymer derivatives
EP2263684A1 (en) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
AU2004279895A1 (en) 2003-10-10 2005-04-21 Xencor, Inc Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
EP2407470A3 (en) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005053730A1 (en) * 2003-12-05 2005-06-16 Kirin Beer Kabushiki Kaisha Therapeutic agent for terminal heart failure
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
EP1730167B1 (en) * 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
EP2335715A3 (en) 2004-02-11 2013-12-18 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs and polypeptides comprising the same
NZ548978A (en) 2004-02-11 2009-10-30 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005084303A2 (en) * 2004-03-01 2005-09-15 Enzon Pharmaceuticals, Inc. Interferon-beta polymer conjugates
AU2005229001A1 (en) * 2004-03-23 2005-10-13 Amgen Inc. Chemically modified protein compositions and methods
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
MXPA06013412A (en) 2004-05-19 2007-01-23 Maxygen Inc Interferon-alpha polypeptides and conjugates.
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
KR101699142B1 (en) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 Novel antigen-binding polypeptides and their uses
NZ552029A (en) 2004-06-25 2009-01-31 Takeda Pharmaceutical Metastin derivatives and use thereof
EP1771197A2 (en) * 2004-06-30 2007-04-11 Egen Corporation Pegylated interferon alpha-1b
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
MX2007002029A (en) 2004-08-19 2007-03-28 Biogen Idec Inc Neublastin variants.
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
EP2301963A1 (en) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006055260A2 (en) * 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
NZ555533A (en) 2004-12-13 2010-03-26 Amylin Pharmaceuticals Inc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP1836298B1 (en) * 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
US7816320B2 (en) * 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
DK1828224T3 (en) 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
ES2449195T3 (en) 2005-01-10 2014-03-18 Ratiopharm Gmbh Glycopegylated granulocyte colony stimulating factor
JP5735194B2 (en) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド Biologically active protein with improved in vivo half-life
CN101119743B (en) * 2005-01-31 2012-09-26 株式会社Eci Immunopotentiating agent
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
US20090286723A1 (en) * 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP2390264A1 (en) * 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
ES2330671T3 (en) 2005-03-31 2009-12-14 Amylin Pharmaceuticals, Inc. AMILINA AND AMILINA AGONISTS FOR THE TREATMENT OF PSYCHIATRIC DISEASES AND DISORDERS.
CA2602654A1 (en) 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
ES2856881T3 (en) 2005-04-11 2021-09-28 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and their use
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
CA2607844C (en) 2005-06-01 2012-07-10 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
TW200722521A (en) * 2005-06-01 2007-06-16 Alza Corp Novel bioconjugation reactions for acylating polyethylene glycol reagents
WO2007009208A1 (en) * 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
ATE529442T1 (en) * 2005-06-03 2011-11-15 Ambrx Inc IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES
KR100694994B1 (en) * 2005-06-13 2007-03-14 씨제이 주식회사 Human Granulocyte-Colony Stimulating Factor Isoforms
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
JP2008546708A (en) 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Use of sanglifehrin in HCV
ES2553160T3 (en) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered Factor VII proteins comprising at least one non-native cysteine
CA2612901A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
WO2007011802A1 (en) 2005-07-18 2007-01-25 Nektar Therapeutics Al, Corporation Method for preparing branched functionalized polymers using branched polyol cores
KR100735784B1 (en) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof
BRPI0613962A2 (en) 2005-07-25 2009-03-24 Intermune Inc innovative macrocyclic hepatitis c virus replication inhibitors
WO2007015591A1 (en) * 2005-08-02 2007-02-08 Cheil Industries Inc. Epoxy resin composition for packaging semiconductor device
JP2009503111A (en) * 2005-08-04 2009-01-29 ネクター セラピューティックス エイエル,コーポレイション G-CSF moiety and polymer composite
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
HUE045165T2 (en) 2005-08-19 2019-12-30 Amylin Pharmaceuticals Llc Exendin for treating diabetes and reducing body weight
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
US20090304754A1 (en) * 2005-10-12 2009-12-10 Srebrenka Robic Pegylated glutenase polypeptides
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
AU2006304856A1 (en) * 2005-10-21 2007-04-26 Synageva Biopharma Corp. Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
DE602006020480D1 (en) * 2005-11-08 2011-04-14 Ambrx Inc ACCELERATOR FOR THE MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
PT2339014E (en) * 2005-11-16 2015-10-13 Ambrx Inc Methods and compositions comprising non-natural amino acids
EP1968635B1 (en) * 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP5738516B2 (en) 2005-12-30 2015-06-24 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド Sustained release of neuregulin to improve cardiac function
AU2007205545B9 (en) 2006-01-12 2012-10-18 Hokusan Co. Ltd. Oral composition containing interferon-alpha
CN100475270C (en) * 2006-01-20 2009-04-08 清华大学 Medicine for treating tumor, and application thereof
AR059193A1 (en) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag MODULATION OF THE ACTIVITY OF MDL-1 FOR THE TREATMENT OF INFLAMMATORY DISEASES
KR101513732B1 (en) 2006-02-21 2015-04-21 넥타르 테라퓨틱스 Segmented degradable polymers and conjugates made therefrom
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
EP2010569A4 (en) 2006-03-20 2009-09-09 Xoma Technology Ltd Human antibodies specific for gastrin materials and methods
WO2007115150A2 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Binding partners with immunoglobulin domains modified to have extended half-life
CA2643680A1 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors and their uses
JO3324B1 (en) 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
US8299024B2 (en) * 2006-05-12 2012-10-30 Amylin Pharmaceuticals, Llc Methods to restore glycemic control
RU2008150314A (en) 2006-05-19 2010-06-27 Гликофи, Инк. (Us) Erythropoietin Compositions
EP2029738A2 (en) 2006-05-24 2009-03-04 Novo Nordisk Health Care AG Factor ix analogues having prolonged in vivo half life
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
JP2009541333A (en) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
EP2049151A4 (en) * 2006-07-17 2010-03-24 Quintessence Biosciences Inc Methods and compositions for the treatment of cancer
CN101516388B (en) * 2006-07-21 2012-10-31 诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences
US8299015B2 (en) * 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
EP2054074B8 (en) 2006-08-04 2014-11-12 Prolong Pharmaceuticals, LLC Modified erythropoietin
ITMI20061624A1 (en) * 2006-08-11 2008-02-12 Bioker Srl SINGLE-CONJUGATE SITE-SPECIFIC OF G-CSF
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CL2007002502A1 (en) 2006-08-31 2008-05-30 Hoffmann La Roche VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE.
AU2007291501B2 (en) * 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
WO2008030614A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
DK2615108T3 (en) * 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
WO2008030613A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
BRPI0719446A2 (en) 2006-09-28 2013-12-10 Schering Corp Use of pegylated IL-10 to treat cancer
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
DK2068907T3 (en) * 2006-10-04 2018-01-15 Novo Nordisk As GLYCEROL BOND PEGYLED SUGAR AND GLYCOPE Peptides
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
CA2667678A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
JO3048B1 (en) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co Metastin Derivatives And Use Thereof
KR101079993B1 (en) * 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
EP2727936B1 (en) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
CN101245109B (en) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 Polyglycol single-modificatory recombined human granular leukocyte colony stimulating factor mutant and preparation method thereof
KR20140012199A (en) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 Modified fgf-21 polypeptides and their uses
KR20100016160A (en) 2007-04-03 2010-02-12 바이오제너릭스 에이지 Methods of treatment using glycopegylated g-csf
JP2008266219A (en) * 2007-04-20 2008-11-06 National Institute Of Advanced Industrial & Technology Protein not containing lysine and cysteine residues
CA2685686A1 (en) 2007-05-01 2008-11-13 Biogen Idec Ma Inc. Neublastin polypeptides for use increasing vascularization in a tissue
CN103965347B (en) 2007-05-02 2017-07-18 Ambrx公司 Modified interferon beta polypeptides and its purposes
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
JP2010531135A (en) * 2007-06-04 2010-09-24 ノボ ノルディスク アクティーゼルスカブ O-linked glycosylation using N-acetylglucosaminyltransferase
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US20110159523A1 (en) * 2007-06-27 2011-06-30 Cedars-Sinai Medical Center N-terminal specific chemical labeling for proteomics applications
EA201070187A1 (en) 2007-07-26 2010-08-30 Эмджен Инк. MODIFIED ENZYMES LECITHIN-CHOLESTEROL ACYLTRANSFERASE
CN101352573B (en) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 Recombinant human granulocyte colony stimulating factor lysine defect body modified by polyethyleneglycol
EP2581441A1 (en) 2007-08-09 2013-04-17 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
PT2197919E (en) 2007-08-27 2014-07-17 Ratiopharm Gmbh Liquid formulation of g-csf conjugate
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8758761B2 (en) * 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
WO2009055014A2 (en) * 2007-10-23 2009-04-30 Nektar Therapeutics Al, Corporation Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
AU2008326324B9 (en) 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
WO2009073977A1 (en) * 2007-12-13 2009-06-18 Biovectra Inc. Polypeptides modified by protein trans-splicing technology
WO2009086356A2 (en) 2007-12-27 2009-07-09 Baxter International Inc. Method and compositions for specifically detecting physiologically acceptable polymer molecules
CN102037004A (en) * 2008-01-08 2011-04-27 生物种属学股份公司 Glycoconjugation of polypeptides using oligosaccharyltransferases
US20100316702A1 (en) * 2008-01-08 2010-12-16 The Regents Of The University Of California Compositions and methods for regulating erythropoeitin expression and ameliorating anemia and stimulating erythropoiesis
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
LT2245145T (en) 2008-01-18 2017-04-10 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2248832B1 (en) 2008-02-18 2014-09-03 Jiangsu Hengrui Medicine Co., Ltd. A g-csf conjugate modified by water-soluble polymer
ES2476690T3 (en) 2008-02-27 2014-07-15 Novo Nordisk A/S Factor VIII conjugated molecules
TWI395593B (en) 2008-03-06 2013-05-11 Halozyme Inc In vivo temporal control of activatable matrix-degrading enzymes
BRPI0822530B1 (en) * 2008-04-03 2022-03-22 Biosteed Gene Expression Tech. Co., Ltd Method of preparing a polyethylene glycolated human growth hormone (peg-modified), peg-modified human growth hormone of lower apparent molecular weight and its use, preparation of peg-modified human growth hormone of lower apparent molecular weight and its method of preparation and composition
BRPI0911266A2 (en) * 2008-04-03 2015-09-29 Hoffmann La Roche pegylated insulin-like growth factor assay
EP2285402A2 (en) 2008-04-14 2011-02-23 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
EP2303313B1 (en) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
PE20091931A1 (en) 2008-05-22 2009-12-31 Bristol Myers Squibb Co MULTIVALENT FIBRONECTIN-BASED FRAME DOMAIN PROTEINS
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
GB0811743D0 (en) 2008-06-26 2008-07-30 Hemosol Biopharma Inc Composition
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
UA118536C2 (en) * 2008-07-23 2019-02-11 Амбркс, Інк. MODIFIED Bovine granulocyte colony-stimulating factor polypeptide and its application
SI2314609T1 (en) * 2008-07-30 2017-05-31 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
TWI421093B (en) * 2008-07-31 2014-01-01 Pharmaessentia Corp Peptide-polymer conjugates
MX2011001583A (en) 2008-08-11 2011-04-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates.
EP2331139B1 (en) 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
MX348657B (en) 2008-09-26 2017-06-21 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines.
EP3216800A1 (en) 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP2334695B1 (en) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Therapeutic ribonucleases
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010045321A2 (en) 2008-10-15 2010-04-22 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
PT2349342T (en) 2008-10-17 2018-10-26 Baxalta Inc Modified blood factors comprising a low degree of water soluble polymer
BRPI0919827B8 (en) 2008-10-20 2021-05-25 Usv Ltd processes for increasing the yield of an r-methug-csf pegylation reaction process for gram scale production of peg- r-methug-csf
US9274122B2 (en) * 2008-10-21 2016-03-01 Baxalta Incorporated Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)
CA2742064A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
IT1392655B1 (en) 2008-11-20 2012-03-16 Bio Ker S R L SITE-SPECIFIC MONOCONJUGATED INSULINOTROPIC GLP-1 PEPTIDES.
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
DK3037529T3 (en) 2008-12-09 2019-05-20 Halozyme Inc EXTENDED SOLUBLE PH20 POLYPEPTIDES AND USE THEREOF
PL2356467T3 (en) 2008-12-11 2013-12-31 Baxalta Inc Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
EP3348281B1 (en) 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
DK3248610T3 (en) 2009-05-05 2024-01-15 Amgen Inc FGF21 MUTANTS AND USES THEREOF
ES2904360T3 (en) 2009-05-20 2022-04-04 Biomarin Pharm Inc C-type natriuretic peptide variants
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
WO2010148413A2 (en) 2009-06-19 2010-12-23 Medimmune, Llc Protease variants
AU2010265964B2 (en) 2009-06-25 2014-09-18 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
JP5734985B2 (en) 2009-09-17 2015-06-17 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA Stable co-formulations of hyaluronidase and immunoglobulin and methods for their use
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
EP2480578A4 (en) * 2009-09-25 2013-04-17 Vybion Inc Polypeptide modification
US9315860B2 (en) 2009-10-26 2016-04-19 Genovoxx Gmbh Conjugates of nucleotides and method for the application thereof
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
JP2013509422A (en) 2009-10-30 2013-03-14 シーエヌエス セラピューティクス,インク. Improved neurturin molecule
MX2012005912A (en) 2009-11-23 2012-10-05 Amylin Pharmaceuticals Inc Polypeptide conjugate.
JP6184695B2 (en) 2009-12-04 2017-08-23 ジェネンテック, インコーポレイテッド Multispecific antibodies, antibody analogs, compositions and methods
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
CN102753573A (en) 2009-12-21 2012-10-24 Ambrx公司 Modified bovine somatotropin polypeptides and their uses
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
NZ602255A (en) * 2010-03-04 2014-04-30 Pfenex Inc Method for producing soluble recombinant interferon protein without denaturing
PL2552949T3 (en) 2010-04-01 2017-01-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CN103096911B (en) 2010-04-27 2018-05-29 Atyr 医药公司 Treatment relevant with the protein fragments of Isoleucyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
CN103097523B (en) 2010-04-29 2016-09-28 Atyr医药公司 The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Asparaginyl-tRNA synthetase finds
CN102234310B (en) * 2010-04-30 2017-02-08 杭州九源基因工程有限公司 Polyethylene glycol modified protein separating and purifying method
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
EP2566496B1 (en) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
CN103200953B (en) 2010-05-14 2017-02-15 Atyr 医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096914B (en) 2010-05-17 2015-08-12 Atyr医药公司 The innovation of the treatment relevant to the protein fragments of Leucyl-tRNA synthetase, diagnosis and antibody compositions finds
MX2012013375A (en) 2010-05-17 2013-04-11 Cebix Inc Pegylated c-peptide.
CN103180339B (en) 2010-05-26 2016-04-27 百时美施贵宝公司 There is the scaffold protein based on fibronectin of the stability of improvement
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
IN2012MN02896A (en) 2010-06-24 2015-06-12 Panmed Ltd
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
WO2012007324A2 (en) 2010-07-15 2012-01-19 Novo Nordisk A/S Stabilized factor viii variants
US9878046B2 (en) 2010-07-20 2018-01-30 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
AR082319A1 (en) 2010-07-22 2012-11-28 Biomarin Pharm Inc PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2446173C1 (en) * 2010-08-13 2012-03-27 Зао "Биокад" New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522B1 (en) 2010-08-17 2021-05-25 Ambrx, Inc. modified relaxin polypeptides comprising a non-naturally encoded amino acid, their method of preparation and their use, as well as nucleic acid and host cell
CN103108650A (en) 2010-08-25 2013-05-15 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
CN103209992A (en) 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 Factor viii variants having a decreased cellular uptake
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
PT2621519T (en) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Leptin-abd fusion polypeptides with enhanced duration of action
KR20140035305A (en) 2010-10-05 2014-03-21 노파르티스 아게 New treatments of hepatitis c virus infection
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN103933577B (en) * 2010-10-25 2014-12-10 北京凯因科技股份有限公司 Preparation and application of recombinant interferon variant polyethylene glycol conjugate
CN102453089B (en) * 2010-10-25 2014-06-04 北京凯因科技股份有限公司 Preparation and application of recombinant consensus interferon mutant polyethylene glycol conjugate
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
RU2013123793A (en) 2010-11-24 2014-12-27 Лексикон Фармасьютикалз, Инк. ANTIBODIES RELATING TO NOTUM PECTINACETHYLESTERASE
RU2013129824A (en) 2010-11-30 2015-01-10 Новартис Аг NEW TREATMENT OF HEPATITIS C VIRUS INFECTION
CN102485742A (en) * 2010-12-02 2012-06-06 山东新时代药业有限公司 Preparation method and separation and purification method of polyethylene glycol single modified recombinant human granulocyte-colony stimulating factor
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
AU2012236889A1 (en) * 2011-03-25 2013-05-09 The Trustees Of Columbia University In The City Of New York Pegylated human HDL particle and process for production thereof
BR112013025021A2 (en) 2011-03-31 2017-03-01 Novartis Ag alisporivir to treat hepatitis virus infections c.
PT2694087E (en) 2011-04-01 2015-04-09 Novartis Ag Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
BR112013025934A2 (en) 2011-04-13 2016-09-06 Debiopharm Int Sa treatment of hepatitis c virus infection with alisporivir
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
BR112013030958B1 (en) 2011-06-03 2022-02-08 Xoma Technology Ltd ANTIBODY BINDING GROWTH TRANSFORMATION FACTOR BETA, PHARMACEUTICAL COMPOSITION, USES THEREOF, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, AND METHOD FOR PRODUCTION OF AN ANTIBODY
CN103889443A (en) 2011-06-17 2014-06-25 哈洛齐梅公司 Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
WO2013003593A1 (en) 2011-06-28 2013-01-03 Alternative Innovative Technologies Llc Methods of use of hsp70 for increased performance or hsp70 related disorders
BR112014000055A2 (en) 2011-07-01 2017-06-13 Bayer Ip Gmbh relaxin fusion polypeptides and uses thereof
PL2717917T3 (en) 2011-07-05 2016-12-30 P97-antibody conjugates
DK2729160T3 (en) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc MANIPULATED POLYPEPTIDES WHICH HAVE IMPROVED EFFECT TIME AND REDUCED IMMUNOGENICITY
CN102952067A (en) * 2011-08-30 2013-03-06 苏州欣诺科生物科技有限公司 Pyridoxal derivative for pegylation modification of N terminal of protein and preparation method and application thereof
AU2012301769B2 (en) 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
JO3476B1 (en) 2011-09-26 2020-07-05 Novartis Ag Fusion proteins for treating metabolic disorders
TW201315742A (en) 2011-09-26 2013-04-16 Novartis Ag Dual fuction proteins for treating metabolic disorders
US20140228281A1 (en) 2011-09-27 2014-08-14 Novartis Ag Alisporivr for treatment of hepatitis c virus infection
US9937241B2 (en) 2011-10-14 2018-04-10 Alternative Innovative Technologies Llc Degradation resistant HSP70 formulations and uses thereof
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP2771300B1 (en) 2011-10-25 2017-12-20 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
JP2015504038A (en) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Fibronectin binding domain with reduced immunogenicity
CN104220086A (en) 2011-11-17 2014-12-17 塞比克斯股份公司 PEGylated C-peptide
WO2013101509A2 (en) 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof
IL298330A (en) 2011-12-30 2023-01-01 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
DK2809350T3 (en) 2012-01-30 2019-01-28 Arecor Ltd STABILIZED Aqueous Antibody Preparations
KR20140123571A (en) 2012-02-16 2014-10-22 에이티와이알 파마, 인코포레이티드 Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
SG11201405276PA (en) 2012-02-27 2014-10-30 Amunix Operating Inc Xten conjugate compositions and methods of making same
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
WO2013134138A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
JP2015509980A (en) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy to treat HCV infection in a population of HCV-HIV co-infected patients
JP2015512900A (en) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy to treat HCV infection in a special patient genotype subpopulation
CN104411332B (en) 2012-03-30 2018-11-23 索伦托治疗有限公司 Human antibody in conjunction with VEGFR2
EA031986B1 (en) 2012-04-04 2019-03-29 Галозим, Инк. Method and combination for treating solid tumor cancer and kit comprising the combination
KR20220084444A (en) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Antigen binding proteins that bind pd-l1
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
EP2864358B1 (en) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
ES2611788T3 (en) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates thereof, methods for their preparation and methods for use
JP6433424B2 (en) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド Dephosphorylated lysosomal storage disease protein and method of use thereof
BR112015004022B1 (en) 2012-08-31 2023-04-25 Sutro Biopharma, Inc MODIFIED AMINO ACIDS COMPRISING AN AZID GROUP
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc Compounds and methods for producing a conjugate
CA2890906A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
CN103908660B (en) * 2013-01-05 2015-02-04 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF pharmaceutical composition and preparation method thereof
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
CN103113466B (en) * 2013-03-01 2015-06-03 中国科学院过程工程研究所 Recombinant human interferon beta-1b modified by polyethylene glycol and preparation method of recombinant human interferon beta-1b
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
BR112015022416A2 (en) 2013-03-13 2017-10-24 Bioasis Technologies Inc p97 fragments and their uses
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
JP2016519108A (en) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド Method for using interleukin-10 for the treatment of diseases and disorders
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
TW201534726A (en) 2013-07-03 2015-09-16 Halozyme Inc Thermally stable PH20 hyaluronidase variants and uses thereof
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
WO2015049630A1 (en) 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
KR20160079114A (en) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 Methods of using interleukin-10 for treating diseases and disorders
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
UY35874A (en) 2013-12-12 2015-07-31 Novartis Ag A PROCESS FOR THE PREPARATION OF A COMPOSITION OF PEGILATED PROTEINS
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
EP4223317A3 (en) 2014-06-12 2023-09-27 RA Pharmaceuticals, Inc. Modulation of complement activity
CN107148282A (en) 2014-08-22 2017-09-08 索伦托治疗有限公司 With reference to CXCR3 antigen-binding proteins
HUE043847T2 (en) 2014-08-28 2019-09-30 Halozyme Inc Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EA201700181A1 (en) 2014-10-14 2017-09-29 Галозим, Инк. COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
JP2017536098A (en) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド Interleukin-15 composition and use thereof
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20240024362A (en) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 Modified fgf-21 polypeptides and uses thereof
EA037151B1 (en) 2014-11-06 2021-02-11 Фармаэссентия Корпорейшн Method of treatment using pegylated interferon
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
CN104491843B (en) * 2015-01-23 2017-09-12 石药集团百克(山东)生物制药有限公司 A kind of polyethyleneglycol modified rhG CSF active pharmaceutical compositions
EP3988110A1 (en) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US10335492B2 (en) * 2015-03-03 2019-07-02 Nansha Biologics (Hong Kong) Limited Increasing serum half-life of human IL-11 variants by N-terminal branched PEGylation
EP3265491A1 (en) 2015-03-03 2018-01-10 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
JP6525171B2 (en) 2015-04-13 2019-06-05 国立研究開発法人産業技術総合研究所 Circularized cytokine and method for producing the same
KR20170141692A (en) 2015-05-01 2017-12-26 알리스타 파마슈티컬즈, 인크. Adiponectin peptide mimetics for treating ocular disorders
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
AU2016304588A1 (en) 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
JP7053453B2 (en) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド How to use interleukin 10 to treat diseases and disorders
EP3355908A1 (en) 2015-10-01 2018-08-08 Amgen Inc. Treatment of bile acid disorders
US10935276B2 (en) 2015-10-20 2021-03-02 Steven Michalski Air mixing device
US11202819B2 (en) 2015-12-08 2021-12-21 Biomarin Pharmaceutical Inc. Use of C-type natriuretic peptide variants to treat osteoarthritis
MX2018007352A (en) 2015-12-16 2019-05-16 Ra Pharmaceuticals Inc Modulators of complement activity.
US10118963B2 (en) 2016-01-29 2018-11-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
JP7148493B2 (en) 2016-08-01 2022-10-05 ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
BR112019011053A2 (en) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc complement activity modulators
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110637027A (en) 2017-02-08 2019-12-31 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
KR102020995B1 (en) 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
US11492493B2 (en) 2017-12-26 2022-11-08 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
JP2021509805A (en) 2017-12-27 2021-04-08 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ Polypeptide showing granulocyte colony stimulating factor activity
EP3765484A4 (en) * 2018-03-14 2021-12-22 Ba, Yong Pegylated antifreeze proteins and methods of making and using the same
EP3775052B1 (en) 2018-03-30 2024-06-05 Becton, Dickinson and Company Water-soluble polymeric dyes having pendant chromophores
MA52347A (en) 2018-04-24 2021-03-03 Amgen Inc PROCESS FOR THE MANUFACTURING OF INJECTABLE PHARMACEUTICAL COMPOSITIONS
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR102167755B1 (en) 2018-05-23 2020-10-19 주식회사 큐어바이오 Fragmented GRS polypeptide, mutants thereof and use thereof
CA3107332A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies Inc. Treatment of lymphatic metastases
US20220056093A1 (en) 2018-09-11 2022-02-24 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP3867265A1 (en) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
EP3902913A1 (en) 2018-12-28 2021-11-03 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
BR112021015832A2 (en) 2019-02-12 2022-01-18 Ambrx Inc Compositions containing antibody-tlr agonist conjugates, methods and uses thereof
US10882954B2 (en) 2019-04-11 2021-01-05 Sunbio Inc. Tertiary alkoxy polyethylene glycol and derivatives thereof
KR20210153092A (en) 2019-04-15 2021-12-16 퀴셀 세라퓨틱스 엘엘씨 Fusion protein composition comprising masked type I interferons (IFNA and IFNB) and antibodies to tumor antigens, for use in the treatment of cancer
WO2020213015A1 (en) * 2019-04-15 2020-10-22 Nof Corporation Conjugate of bio-related substance and block polymer, and block polymer derivative for obtaining said conjugate
KR20220151202A (en) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 Interleukin-2 polypeptide conjugates and methods of use thereof
EP4121448A2 (en) 2020-03-20 2023-01-25 Amgen Inc. Determination of free n-terminus of pegfilgrastim using an acid protease
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
JP2023538071A (en) 2020-08-20 2023-09-06 アンブルックス,インコーポレイテッド Antibody-TLR agonist conjugates, methods and uses thereof
US11602598B1 (en) * 2020-08-27 2023-03-14 Fresenius Kabi Deutschland Gmbh Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
US11952461B2 (en) 2021-03-22 2024-04-09 Sunbio, Inc. Siloxy polyethylene glycol and derivatives thereof
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1609546A (en) 1925-11-19 1926-12-07 Petroleum Rectifying Co Process of separating water from emulsions
DE2047413C3 (en) 1970-09-26 1980-05-29 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Process for the production of peptides in a homogeneous phase
US4002714A (en) * 1972-08-14 1977-01-11 Fumio Usui Method for producing a tapered pipe of reinforced synthetic resin
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE2930542A1 (en) 1979-07-27 1981-02-12 Hoechst Ag NEW INSULINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3139483C2 (en) 1981-10-03 1985-06-13 Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel Method and circuit arrangement for increasing contrast
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS58225025A (en) * 1982-06-24 1983-12-27 Nippon Chem Res Kk Long active composition
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JPS61227526A (en) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
JPS6142558A (en) 1984-08-06 1986-03-01 Matsushita Electric Works Ltd Amino resin molding material
JPS62129298A (en) 1985-12-02 1987-06-11 Chugai Pharmaceut Co Ltd Novel polypeptide
WO1986004605A1 (en) 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US5532341A (en) 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
ES8800982A1 (en) 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Modified enzymes, production and use thereof.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (en) 1985-08-23 1988-03-10 麒麟麦酒株式会社 DNA encoding multipotent granulocyte colony stimulating factor
JPH0657152B2 (en) 1985-09-17 1994-08-03 中外製薬株式会社 CSF genes
JP2514950B2 (en) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー Chemically modified protein, its production method and intermediate
DK203187A (en) * 1986-04-22 1987-10-23 Immunex Corp HUMAN G-CSF PROTEIN EXPRESSION
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
JPS63126900A (en) 1986-06-26 1988-05-30 Takeda Chem Ind Ltd Chemically modified protein
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS63152393A (en) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd Glycosyl derivative
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
WO1988001297A1 (en) 1986-08-11 1988-02-25 Cetus Corporation Expression of g-csf and muteins thereof
JPS6360938A (en) 1986-09-02 1988-03-17 Meiji Milk Prod Co Ltd Plasminogen activator of modified tissue type and production thereof
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
DK174044B1 (en) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptide derived from human granulocyte colony stimulating factor, and method of preparation thereof, DNA encoding said polypeptide, recombinant plasmid containing said DNA, and microorganisms containing said recombinant plasmid .......
JPH086063B2 (en) 1987-07-22 1996-01-24 日本ペイント株式会社 Hydrophilic surface treatment agent and treatment method
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JP2958019B2 (en) 1988-05-06 1999-10-06 住友製薬株式会社 Polyethylene glycol derivative, modified peptide and method for producing the same
JP2796388B2 (en) * 1988-05-13 1998-09-10 アムジエン・インコーポレーテツド Method for purifying G-CSF
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4660789A (en) 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
JPH04503607A (en) 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド Immobilized cytokines
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
KR920701252A (en) * 1989-10-10 1992-08-11 스티븐 엠. 오드레 Granulocyte colony stimulating factors and methods for treating or preventing infectious diseases in dogs and cats using them
JP2978187B2 (en) 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 Method for producing modified superoxide dismutase
JPH04218000A (en) * 1990-02-13 1992-08-07 Kirin Amgen Inc Modified polypeptide
DE4009661C1 (en) 1990-03-26 1991-03-07 Aisa Automation Industrielle S.A., Vouvry, Ch
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (en) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh MUTEINE OF THE GRANULOCYTE-STIMULATING FACTOR (G-CSF)
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
ES2128348T3 (en) * 1990-10-17 1999-05-16 Amgen Inc OBTAINING COMPOSITIONS FOR THE TREATMENT OF ALTERATIONS OF CELL PROLIFERATION.
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
CH682636A5 (en) * 1990-12-21 1993-10-29 Bucher Guyer Ag Masch A method for the selective removal of sugar from beverages.
ATE190629T1 (en) 1991-01-18 2000-04-15 Amgen Inc METHODS OF TREATING DISEASES CAUSED BY TUMOR NECROSIS FACTOR
DE4105480A1 (en) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5197592A (en) * 1991-08-05 1993-03-30 Fmc Corporation Wire frame idler roll support
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
JP3235855B2 (en) 1991-12-19 2001-12-04 住友製薬株式会社 Cell adhesion active peptide and its modified polymer
JP3387519B2 (en) * 1992-03-04 2003-03-17 株式会社日立製作所 Information recording / reproducing method and disk-shaped recording medium
FR2692736B1 (en) 1992-06-23 1996-12-20 Thomson Csf HIGH AND MEDIUM POWER RADIOELECTRIC FILTER.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0679095A1 (en) 1992-11-25 1995-11-02 Amgen Boulder Inc. Modified insulin-like growth factors
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5589356A (en) 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
US5481571A (en) 1993-11-12 1996-01-02 Pacific Communication Sciences, Inc. Method and apparatus for switching between radio frequency circuits
SK166695A3 (en) * 1994-03-31 1997-02-05 Amgen Inc Mgdf polypeptide for stimulating growth and megakaryocyte differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5661122A (en) 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
JP3708151B2 (en) 1994-12-15 2005-10-19 協和醗酵工業株式会社 Quantification of PEGylated human granulocyte colony-stimulating factor
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR101441331B1 (en) 2013-07-19 2014-09-17 주식회사 슈프리마 Optical type fingerprint recognition apparatus

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026182A (en) * 2015-09-18 2018-05-11 国立大学法人宫崎大学 Long-acting adrenomedulin derivative
CN112710826A (en) * 2020-11-17 2021-04-27 北京九强生物技术股份有限公司 Coating and sealing method for improving stability of reagent
CN113214328A (en) * 2021-05-08 2021-08-06 宁波经济技术开发区弘翔生化科技有限公司 Double-aqueous-phase system and monosaccharide separation method based on double-aqueous-phase system
CN113214328B (en) * 2021-05-08 2022-06-28 宁波经济技术开发区弘翔生化科技有限公司 Double-aqueous-phase system and monosaccharide separation method based on double-aqueous-phase system

Also Published As

Publication number Publication date
CN1896103A (en) 2007-01-17
US5824784A (en) 1998-10-20
EP0733067A1 (en) 1996-09-25
JPH0925298A (en) 1997-01-28
AU706700B2 (en) 1999-06-24
US20100310510A1 (en) 2010-12-09
ES2131811T3 (en) 1999-08-01
HK1008787A1 (en) 1999-05-21
DK0733067T3 (en) 1999-11-01
CA2472085A1 (en) 1996-04-25
JP3177251B2 (en) 2001-06-18
US8258262B2 (en) 2012-09-04
CN1071760C (en) 2001-09-26
US7090835B2 (en) 2006-08-15
JP2003155299A (en) 2003-05-27
JP3177449B2 (en) 2001-06-18
DE10299044I1 (en) 2003-03-27
US20060233746A1 (en) 2006-10-19
EP2392594A1 (en) 2011-12-07
ATE277078T1 (en) 2004-10-15
ATE179991T1 (en) 1999-05-15
EP1564219A1 (en) 2005-08-17
ZA951008B (en) 1996-10-18
US20040181035A1 (en) 2004-09-16
IL112585A0 (en) 1995-05-26
JPH11310600A (en) 1999-11-09
DE69533556D1 (en) 2004-10-28
MX9602259A (en) 1997-02-28
HK1008826A1 (en) 1999-05-21
EP0822199A2 (en) 1998-02-04
JP2006077021A (en) 2006-03-23
IL134754A (en) 2009-11-18
NL300106I2 (en) 2003-02-03
EP0822199B1 (en) 2004-09-22
JP5350330B2 (en) 2013-11-27
JP2003327600A (en) 2003-11-19
DE69533556T2 (en) 2005-10-20
CN101381409B (en) 2013-03-27
CN1229388C (en) 2005-11-30
EP0822199A3 (en) 2001-10-24
JP2010215657A (en) 2010-09-30
CA2178752A1 (en) 1996-04-25
CN1313343A (en) 2001-09-19
CA2307142C (en) 2010-09-21
EP2399930A1 (en) 2011-12-28
KR100261030B1 (en) 2000-06-15
LU91006I2 (en) 2003-03-31
CA2307142A1 (en) 1996-04-25
JPH09506116A (en) 1997-06-17
ES2224197T3 (en) 2005-03-01
US7662933B2 (en) 2010-02-16
NL300106I1 (en) 2003-01-06
JP2006045243A (en) 2006-02-16
DE69509628D1 (en) 1999-06-17
EP0733067B1 (en) 1999-05-12
KR100248111B1 (en) 2000-03-15
DE69509628T2 (en) 1999-09-16
IL112585A (en) 2000-08-31
US5985265A (en) 1999-11-16
AU1841995A (en) 1996-05-06
CA2178752C (en) 2000-10-17
IL134754A0 (en) 2001-04-30
NZ281469A (en) 1997-04-24
US20120296072A1 (en) 2012-11-22
WO1996011953A1 (en) 1996-04-25
GR3030526T3 (en) 1999-10-29
PT822199E (en) 2005-01-31
US20130189219A1 (en) 2013-07-25
CN1139932A (en) 1997-01-08

Similar Documents

Publication Publication Date Title
CN101381409B (en) N-terminally chemically modified protein compositions and methods
US6956027B2 (en) N-terminally chemically modified protein compositions and methods
Gabriel et al. United States Patent (19)
AU741659B2 (en) N-terminally chemically modified protein compositions and methods
AU2004235682B2 (en) N-Terminally chemically modified protein compositions and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20150208

Granted publication date: 20130327